Document:

Exhibit 10.05

 

CONFIDENTIAL

 

	CONFIDENTIAL
TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,
WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

LICENSE AGREEMENT REGARDING DIESEL FUEL IN THE
EU

 

This License Agreement
regarding Diesel Fuel in the EU (the “Agreement”) is entered into on March 21, 2016 (the “Effective
Date”) by and among AMYRIS, INC., a corporation organized and existing under the laws of the state of Delaware,
United States of America, with its principal place of business at 5885 Hollis Street, Suite 100, Emeryville, California 94608 (“AMYRIS”),
and Total Energies Nouvelles Activités USA, a société par actions simplifiée organized under
the laws of the Republic of France, with its principal place of business at 24 Cours Michelet, 92800 Puteaux, France (“TOTAL”).
AMYRIS and TOTAL may each be referred to herein individually as a “Party,” and collectively as the “Parties.”

 

BACKGROUND

 

WHEREAS, AMYRIS and Total Gas & Power USA
Biotech, Inc. entered into a technology license, research, development, commercialization and collaboration relationship pursuant
to that certain Technology License, Development, Research and Collaboration Agreement, dated as of June 21, 2010 (the “Original
Collaboration Agreement”), which Original Collaboration Agreement was assigned by Total Gas & Power USA Biotech,
Inc. to TOTAL (then known as Total Gas & Power USA SAS) by letter agreement dated January 11, 2011;

 

WHEREAS, AMYRIS and TOTAL entered into an amendment
of the Original Collaboration Agreement as of November 23, 2011 (“First Amendment”), and subsequently further
amended the Original Collaboration Agreement effective as of July 31, 2012, (“Original Second Amendment”), which
amendment superseded the First Amendment with respect to the matters set forth therein and contemplated that AMYRIS would grant
to a joint venture entity certain licenses and other rights to use certain intellectual property of AMYRIS to Make and Sell JV
Products (as defined in the Original Second Amendment) and conduct certain related activities, in each case, according to the terms
and conditions set forth in a license agreement;

 

WHEREAS, on November
29, 2013, AMYRIS and TOTAL established Total Amyris BioSolutions, B.V., a joint venture entity (“JVCO”),
in order to develop and commercialize JV Products as contemplated in the Original Second Amendment, and in connection with the
establishment of JVCO: (i) AMYRIS entered into a license agreement with JVCO, effective as of December 2, 2013 (“JVCO
License Agreement”), granting to JVCO the contemplated licenses and rights with respect to the JV Products, and (ii)
AMYRIS and TOTAL entered into a letter agreement to clarify (x) the obligations of AMYRIS with regard to the restrictions to be
incorporated in its future agreements regarding the production and commercialization of farnesene and/or farnesane and (y) Section
4.1 of the IP License Agreement (as defined below);

 

WHEREAS, AMYRIS and TOTAL amended the Original
Second Amendment effective as of April 1, 2015, to authorize TOTAL to conduct certain hydrogenation activities and to clarify the
licenses to be granted by TOTAL to AMYRIS and JVCO regarding intellectual property created from such activities (as amended, the
“Second 

 

    	 	1	 

    CONFIDENTIAL

    

Amendment”,
and the Original Collaboration Agreement, as amended by the First Amendment and the Second Amendment, and as may be further amended
from time-to-time, the “Collaboration Agreement”).

 

WHEREAS, on the
date of this Agreement, the Parties now wish to bifurcate the rights previously granted to JVCO, with JVCO retaining the licenses
and rights under the JVCO License Agreement only with respect to JV Products for use as, and in, jet fuels pursuant to the
“Amended and Restated JVCO Jet Fuel License Agreement” entered of even date herewith, and the licenses and rights
under the JVCO License Agreement with respect to JV Products for use as, and in, diesel fuels reverting to AMYRIS except as provided
herein;

 

WHEREAS, with regard to the reverted rights
with respect to products for use as, and in, diesel fuels, the Parties have agreed that AMYRIS would grant certain licenses and
rights to TOTAL and would retain the remainder of such rights for itself and its Affiliates;

 

In order to make such license grants to TOTAL
and to address certain related matters, the Parties desire to enter into this Agreement, subject to the terms and conditions hereof;

 

NOW, THEREFORE, in consideration of the mutual
promises and covenants set forth below and other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Parties agree as follows:

 

Article
1.   DEFINITIONS

 

1.1             
References to definitions in the Collaboration Agreement, including the Second Amendment, are to such definitions as they
exist as of the Effective Date.

 

1.2             
“Affiliate” shall have the meaning set forth in Section 1.1 of the Collaboration Agreement; except that
(i) Novvi LLC and its Affiliates (collectively, “Novvi”) shall not be deemed an Affiliate of AMYRIS under this
Agreement unless AMYRIS’ equity ownership of a Novvi entity exceeds 50%, at which time, the applicable Novvi entity(ies)
will be considered an Affiliate of AMYRIS for purposes of this Agreement, (ii) Company shall not be considered an Affiliate of
AMYRIS nor an Affiliate of TOTAL and neither TOTAL nor AMYRIS shall be considered an Affiliate of Company, and (iii) SMA Indústria
Química S.A and its Affiliates (collectively, “SMA”) shall not be deemed an Affiliate of AMYRIS
under this Agreement unless AMYRIS’ equity ownership of an SMA entity exceeds 50%, at which time, the applicable SMA entity(ies)
will be considered an Affiliate of AMYRIS for purposes of this Agreement. For clarity, the Affiliates of AMYRIS as of the Effective
Date include: AMYRIS Fuels LLC, AB Technologies LLC, and AMYRIS Brasil Ltda. 

 

1.3             
“AMYRIS Certification Materials” means the Diesel Certification Materials (as defined in Section 7 of
the Second Amendment) made or generated by or on behalf of AMYRIS.

    	 	2	 

    CONFIDENTIAL

    

 

1.4             
“AMYRIS Family” means AMYRIS and its Affiliates.  

 

1.5             
“AMYRIS Farnesene Included IP” means any (i) AMYRIS Background IP (as defined in the Collaboration Agreement)
and any AMYRIS Non-Collaboration IP (as defined in the Collaboration Agreement), in each case that is Controlled by AMYRIS or its
Affiliates as of the Second Amendment Date, and (ii) AMYRIS Non-Collaboration IP developed after the Second Amendment Date (other
than by a Third Party Acquirer), in each case, that (x) encompass general means of practicing synthetic biology or (y) are
necessary or useful for the R&D Activities (as defined in the Collaboration Agreement) contemplated in connection with the
Biofene Development Project.

 

1.6             
“AMYRIS Farnesene Production IP” means any Farnesene Production IP owned or Controlled by AMYRIS or its Affiliates
(other than a Third Party Acquirer).

 

1.7             
“AMYRIS Hydrogenation IP” means any AMYRIS Background IP and AMYRIS Non-Collaboration IP in each
case that is Controlled by AMYRIS or its Affiliates (other than a Third Party Acquirer) and is necessary or materially useful in
order to hydrogenate farnesene into farnesane. 

 

1.8             
“AMYRIS Included IP” shall have the meaning provided in Section 1.4 of the Collaboration
Agreement.

 

1.9             
“AMYRIS Licensed IP” means, all Inventions to the extent owned or Controlled by AMYRIS or its Affiliates
(other than a Third Party Acquirer) as of the Effective Date or at any time thereafter during the Term until thirty (30) years
following the Effective Date including, AMYRIS Technology (as defined in Section 1.11 of the Collaboration Agreement), AMYRIS-Owned
Collaboration IP (as defined in Section 1.9 of the Collaboration Agreement), AMYRIS Hydrogenation IP, AMYRIS-Owned Improvement
Scope IP, AMYRIS’ interest in Jointly-Owned Improvement Scope IP (as defined in Section 6.1(e) of the Collaboration Agreement),
Jointly Owned Collaboration IP (as defined in Section 6.1(d)(ii) of the Collaboration Agreement), AMYRIS Farnesene Included IP
and AMYRIS Production IP (as defined herein), and any Invention(s) licensed to AMYRIS by Novvi pursuant to the IP License Agreement
entered by AMYRIS and Novvi on March 26, 2013 and amended on March 21, 2016, (the “IP License Agreement”), and
subject to the terms of Section 2.A(v) below, the AMYRIS Certification Materials, in each case that is necessary or, in the
case of the AMYRIS Farnesene Production IP, useful (i) to develop and/or optimize the processes of making farnesene from the Commercial
Farnesene Strain and purifying it from the fermentation broth and converting farnesene into farnesane and/or (ii) to Make and Sell
(as defined in Section 1.75 of the Collaboration Agreement) Licensed Products. For purposes of this definition and for Sections
2(A)(i)(a), 2(A)(i)(c), 2(A)(i)(d), and 7(D), an item of AMYRIS Licensed IP will be deemed to be necessary with respect to a particular
activity if it is actually used by TOTAL in carrying out such activity.

    	 	3	 

    CONFIDENTIAL

    

 

1.10         
“AMYRIS-Owned Improvement Scope IP” means any and all Improvement Scope IP that is owned by AMYRIS pursuant
to Section 6.1(e) of the Collaboration Agreement.

 

1.11         
“Banked Strain” has the meaning set forth in Section 2.D hereof.

 

1.12         
“Biofene Development Project” means the project and activities described in the Biofene Development
Project Plan.

 

1.13         
“Biofene Development Project Plan” means the written Development Project Plan agreed by AMYRIS and TOTAL
for the research, development, and scale-up production activities to be conducted pursuant to the Second Amendment (as amended
from time to time, if applicable, pursuant to the Collaboration Agreement).

 

1.14         
“Biofene Development Project Extension Agreement” means a written contract between TOTAL and AMYRIS, negotiated
pursuant to the process set forth in Section 2.A(vii) hereof, under which the Parties extend the term of the Biofene Development
Project beyond July 31, 2016 to set forth the Strain engineering and other activities AMYRIS will perform during such extension
period, and the payments TOTAL will make to AMYRIS for AMYRIS’s Biofene Development Project-related activities during this
extension period.

 

1.15         
“By-Product” means any composition other than a Licensed Product that is produced (and has been produced
in greater than de minimis levels in a manufacturing process that is at least a 300 liter scale) (a) as a direct consequence
of the manufacture of a Licensed Product by TOTAL or its Affiliates, Subcontractors or sublicensees, and (b) except in the case
of dead yeast cells, with a weight that is less than 40% of the weight of the applicable Licensed Product concurrently produced
and, in each case, any composition resulting from further purification processing.

 

1.16         
“Change of Control” means the occurrence of any of the following with respect to AMYRIS: (i) the
consolidation of AMYRIS with, or the merger of AMYRIS with or into, another “person” (as such term is used in Rule
13d-3 and Rule 13d-5 of the Exchange Act), or the sale, lease, transfer, conveyance or other disposition, in one or a series of
related transactions, of all or substantially all of the assets of the AMYRIS and its subsidiaries taken as a whole, or the consolidation
of another “person” with, or the merger of another “person” into, AMYRIS, other than in each case pursuant
to a transaction in which the “persons” that “beneficially owned” (as such term is defined in Rule 13d-3
and Rule 13d-5 under the Exchange Act), directly or indirectly, the Voting Shares of AMYRIS immediately prior to the transaction
“beneficially own”, directly or indirectly, Voting Shares representing at least a majority of the total voting power
of all outstanding classes of voting stock of the surviving or transferee person; (ii) the adoption by AMYRIS of a plan relating
to the liquidation or dissolution of AMYRIS, (iii) the consummation of any transaction (including any merger or consolidation)
the result of which is that any “person” becomes the “beneficial owner” directly or indirectly, of more
than 50% of the Voting Shares of the AMYRIS (measured by voting power rather than number of shares); or

 

    	 	4	 

    CONFIDENTIAL

    

(iv) the first day on which a majority of
the members of the AMYRIS board of directors does not consist of Continuing Directors. As used in this definition, “Voting
Shares” of any Person means capital shares or capital stock of such Person which ordinarily has voting power for the
election of directors (or persons performing similar functions) of such Person, whether at all times or only so long as no senior
class of securities has such voting power by reason of any contingency. As used in this definition, “Continuing Director”
means, as of any date of determination, any member of the AMYRIS board of directors who (i) was a member of the AMYRIS Board of
Directors on July 31, 2012 or (ii) was nominated for election or elected to the AMYRIS board of directors with the approval of
a majority of the Continuing Directors who were members of the AMYRIS board of directors at the time of such nomination or election
and who voted with respect to such nomination or election; provided that a majority of the members of the AMYRIS board of directors
voting with respect thereto shall at the time have been Continuing Directors. Notwithstanding the foregoing, an AMYRIS
Change of Control shall not be deemed to have occurred in connection with (A) any acquisition of Amyris by TENA USA (or any
of its Affiliates) or (B) any change in the board of directors of AMYRIS such that it is no longer composed of a majority
of Continuing Directors if any designee of TENA USA (or any of its Affiliates) to the board of directors of AMYRIS approves the
nomination or election of any member of the board of directors of AMYRIS that is not a Continuing Director or if TENA USA (or any
of its Affiliates) votes any Voting Shares in favor of the election of any member of the board of directors of AMYRIS that is not
a Continuing Director. 

 

1.17         
“Commercial Farnesene Strain” means any Commercial Strain (as defined in Section 1.25 of the Collaboration
Agreement) designed for the production of farnesene.

 

1.18         
“Commercial Scale” means with respect to a particular Commercial Farnesene Strain, the use of such Strain
to reproducibly produce farnesene of commercially quality in commercial quantities and at commercially reasonable cost, as shown
by production of [*].

 

1.19         
“Commercial Technology Transfer Package” has the meaning set forth in Section 2.D(i).

 

1.20         
“Confidential Information” has the meaning set forth in Section 6.A hereof.

 

1.21         
“Control” or “Controlled” means, with respect to any Invention, Patent or other intellectual
property right, that the applicable Party or its Affiliates owns or has a license to such Invention, Patent or other intellectual
property right and such applicable Party or its Affiliates has the ability to disclose the same to the other Party and to
grant the other Party a license or a sublicense (as applicable) under the same as provided in this

 

 

 

[*] Certain portions
denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions.

 

    	 	5	 

    CONFIDENTIAL

    

Agreement without violating the terms of any agreement
or other arrangement with any Third Party.

 

1.22         
“Diesel Product” means one or more fermentation-produced isoprenoid(s) that may or may not be hydrogenated
or hydroprocessed, which when blended with petroleum diesel, meet the ASTM D975 specification, the EN590 European standard or the
equivalent of (or successor to) either such standard, in each case, for use as a diesel fuel.

 

1.23         
“Dispute” means any dispute, claim or controversy that arises between the Parties in connection with
this Agreement or any agreement or instrument delivered in connection herewith, or the negotiation, execution, interpretation,
breach, termination invalidity or enforcement hereof or thereof.

 

1.24         
 “Executive Officers” means (a) in the case of AMYRIS, the Chief Commercial Officer or such other officer
designated in writing by the Chief Executive Officer, and (b) in the case of TOTAL, an executive officer nominated by TOTAL at
the time of the Dispute.

 

1.25         
“Farnesane Diesel Product” means a Diesel Product that is farnesane, wherein the isoprenoid is farnesene.

 

1.26         
“Farnesene Production IP” means any and all (a) AMYRIS Farnesene Included IP, (b) Collaboration
IP and (c) Improvement Scope IP, in each case that is necessary or useful to (i) produce farnesene from fermentation of a Farnesene
Strain or (ii) purify such farnesene from the fermentation medium to hydrogenation grade.

 

1.27         
“Farnesene Strain” means any Strain that produces farnesene.

 

1.28         
“Field” means diesel fuel applications.

 

1.29         
“Governmental Entity” shall have the meaning set forth in Section 1.54 of the Collaboration Agreement.

 

1.30         
“Improvement Scope IP” means any and all Inventions that are conceived or reduced to practice on or after
the Effective Date of the Collaboration Agreement by (a) any employee, agent or Third Party contractor of TOTAL or any of
its Affiliates, (b) any employee, agent or Third Party contractor of AMYRIS or any of its Affiliates, or (c) any of the foregoing
jointly, in each case, in the performance of Improvement Scope Activities (x) during the term of the Collaboration Agreement or
(y) during the term that a Licensed Product is being commercialized by TOTAL.

 

1.31         
“Indemnified Party” has the meaning set forth in Section 5.A(iii) hereof.

 

1.32         
“Indemnifying Party” has the meaning set forth in Section 5.A(iii) hereof.

 

1.33         
“Infringement” has the meaning set forth in Section 3.D(i) hereof.

 

    	 	6	 

    CONFIDENTIAL

    

1.34         
“Initial Package” has the meaning in Section 2.D(iii)(a) hereof.

 

1.35         
“Intermediate Strain(s)” means, at a given point in time, (i) the Farnesene Strain then most recently
used by AMYRIS for the commercial Manufacture of farnesene, if any, and (ii) up to ten (10) other Strains developed in the
Biofene Development Project that are most likely to achieve the goals of the Biofene Development Project. The four Intermediate
Strains to be initially escrowed as part of the Initial Package have been selected by the Management Committee (as defined in the
Collaboration Agreement). The Management Committee pursuant to the Second Amendment may periodically designate additional Intermediate
Strain(s) for inclusion as Banked Strains to replace any or all of the four (4) initial Banked Strains, provided that if the Management
Committee is unable to agree upon whether a particular Strain should be designated as an Intermediate Strain, then the TOTAL representative(s)
to the Management Committee shall have the right to make such decision with respect to eight (8) (but not more) of the subject
Strains but in no event may the TOTAL representatives(s) designate more than eight (8) Strains for escrow. Notwithstanding the
above, at any given time, there shall be no more than fourteen (14) Banked Strains.

 

1.36         
“Invention(s)” means, whether or not patentable, any inventions, information, technology, methods, compositions
of matter, formulae and other subject matter (including all related software, workflow, apparatus or arrangement of apparatuses,
knowledge database systems, processes, systems and technology for the design, selection, engineering, development and manufacture
of Strains, Compounds or Products (each, as defined in the Collaboration Agreement), the Strains and the Compounds and the Products
themselves, chemistry, process engineering, materials transformation, Strain or Compound or Product specifications, know-how, trade
secrets, improvements and all intellectual property rights therein or pertaining thereto.

 

1.37         
“IP License Agreement” has the meaning set forth in Section 1.10.

 

1.38         
“Knowledge” means actual or constructive knowledge of any officer of AMYRIS.

 

1.39         
“Known By-Product” means a By-Product that is specified on Exhibit D as of the Effective Date or added
to Exhibit D in accordance with Section 2.H.

 

1.40         
“Legal Requirement” means, with respect to any Party, any federal, state or local law, constitution,
treaty, ordinance, code, edict, writ, decree, rule, regulation, judgment, ruling, injunction or requirement issued, enacted, adopted,
promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Entity that is binding upon
or applicable to such Party, including Environmental Laws (as defined in the Collaboration Agreement) and any of the foregoing
applicable to genetically modified microorganisms, related to food, drugs, health or safety.

 

1.41         
“Licensed Product” means (i) farnesene or farnesane for use in Diesel Product and (ii) Farnesane Diesel
Product.

    	 	7	 

    CONFIDENTIAL

    

 

1.42         
“Lien” means any security interest, pledge, mortgage, lien, charge, adverse claim of ownership or use,
or other encumbrance of any kind.

 

1.43         
“Manufacture” means make and have made (including practicing and using for the foregoing purposes).

 

1.44         
 “Negotiation Period for Biofene Development Project Extension” means the ninety (90) day period described
in Section 2.A(vii).

 

1.45         
“Patent(s)” means (a) all national, regional and international patents and patent applications, including
provisional patent applications; (b) all patent applications filed either from a patent or patent application described in clause
(a) or from an application claiming priority to a patent or patent application described in clause (a), including divisionals,
continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications; (c) any and
all patents that have issued or in the future issue from the foregoing patent applications (clauses (a) and (b)), including utility
models, petty patents and design patents and certificates of invention; (d) any and all extensions or restorations by existing
or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any
supplementary protection certificates and the like) of the foregoing patents or patent applications (clauses (a), (b) and (c));
and (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction
patent or registration patent or patent of additions to any such foregoing patent applications and patents.

 

1.46         
“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint
venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.

 

1.47         
“Potential Third Party Conflict” has the meaning set forth in Section 2.H(ii).

 

1.48         
“Program Strain” means a Commercial Strain (as defined in Section 1.25 of the Collaboration Agreement)
designed for the production of farnesene that satisfies the criteria of a Commercial Farnesene Strain.

 

1.49         
 “Second Amendment Date” means July 30, 2012.

 

1.50         
“Strain” means any microorganism, including bacteria, yeast, higher fungi and algae, that is tested,
modified or optimized to produce compounds according to the alteration of metabolic pathways, including AMYRIS’ genetically
modified yeast strain that includes the Mevalonate Pathway (as defined in the Collaboration Agreement) from which it is capable
of making an isoprenoid compound.

 

1.51         
“Strain Improvement Technology” means any Invention Controlled by AMYRIS or its Affiliates (other
than a Third Party Acquirer) that is necessary or materially

 

    	 	8	 

    CONFIDENTIAL

    

useful to perform
strain engineering or other genetic manipulation (by any means) in order to genetically manipulate any Strain(s) for the
purpose of developing or improving a Farnesene Strain.

 

1.52         
 “Subcontractor” has the meaning set forth in Section 2.C(ii) hereof.

 

1.53         
“Subject Third Party Agreement” shall have the meaning set forth in Section 4.D(ii) hereof.

 

1.54         
 “Successful Commercial Transfer” means with respect to a particular Commercial Farnesene Strain, the
use of such Strain to reproducibly produce farnesene at Commercial Scale.

 

1.55         
 “Term” has the meaning set forth in Section 7.A hereof.

 

1.56         
“Territory” means the member countries of the European Union as of the Effective Date, which countries
are listed in Exhibit C hereto.

 

1.57         
“Third Party” means a Person other than AMYRIS or TOTAL or an Affiliate of AMYRIS or TOTAL.

 

1.58         
“Third Party Acquirer” means (i) a Third Party that acquires AMYRIS in a Change of Control or acquires
substantially all of the assets of AMYRIS and (ii) any Affiliates of such Third Party (other than the members of AMYRIS Family
as of immediately prior to the AMYRIS transaction described in subparagraph (i)).

 

1.59         
“Third Party Agreement” means any agreement that was entered or is entered by AMYRIS with a Third Party
pursuant to which AMYRIS obtained or obtains a license, with the right to sublicense, of any Inventions, including without limitation
Patents, within the AMYRIS Licensed IP.

 

1.60         
“Third Party Conflict” has the meaning set forth in Section 2.H(i).

 

1.61         
“TOTAL Indemnitees” has the meaning set forth in Section 5.A(ii) hereof.

 

1.62         
“TOTAL Strains” means the Commercial Farnesene Strain(s), the Intermediate Strain(s) and any other Strains
that are genetic manipulations or modifications of any of the foregoing.

 

1.63         
“TOTAL Independent Strain Engineering Patents” means any issued Patent owned by TOTAL or a wholly-owned
Affiliate of TOTAL with respect to an Invention conceived or reduced to practice by or on behalf of TOTAL in connection with the
exercise of the license granted in Section 2.A(i)(b) of this Agreement that claims (a) a Strain including a Mevalonate Pathway
that produces one or more isoprenoid compounds, or (b) methods of using such Strain outside the Field.

 

    	 	9	 

    CONFIDENTIAL

    

Article
2.   LICENSE GRANT AND RELATED TERMS

 

A.               
License to Make and Sell Licensed Products.

 

(i)            License Grants. Subject to Section 2.F below
and Article 7, AMYRIS and its Affiliates hereby grant to TOTAL the following perpetual and irrevocable licenses, with the right
to sublicense through multiple tiers pursuant to Section 2.C below, for the Licensed Products:

 

(a)                  
a non-exclusive, worldwide (subject to Section 2.E(iv) below), royalty-free (subject to Section 2.B below) right and license
under the AMYRIS Licensed IP in each case that is necessary or, in the case of the AMYRIS Farnesene Production IP, useful to develop
and/or optimize the processes of making farnesene from a Commercial Farnesene Strain, purify farnesene from the fermentation broth,
and convert farnesene into farnesane, in each case solely for TOTAL to exercise its licenses under clauses (c) and (d) below;

 

(b)                 
a non-exclusive, worldwide (subject to Section 2.E(iv) below), royalty-free (subject to Section 2.B below) right and license
under the Strain Improvement Technology to optimize and/or engineer, by any means, any Farnesene Strain for use in the Field (including
but not limited to Commercial Farnesene Strains with performance characteristics that exceed Commercial Scale), which license may
be practiced upon the earliest to occur of the following, but in no event before the expiration of the Biofene Development Project:
(1) AMYRIS fails to timely respond or declines to enter into negotiations with TOTAL in respect of a Biofene Development Project
Extension Agreement under Section 2.A(vii), (2) the expiration of the Negotiation Period to Extend the Biofene Development Project,
but only if, the Parties have not executed a Biofene Development Project Extension Agreement as of such expiration, or (3) the
expiration of the Biofene Development Project Extension Agreement. Such license may be practiced for so long as TOTAL is pursuing
the development and/or Manufacture of farnesene for use in the Field;

 

(c)                  
an exclusive (subject to Section 2.A(iii)(a)(1) and 2.A(iii)(b)), royalty-free (subject to Section 2.A(vi) and Section
2.B below) right and license under the AMYRIS Licensed IP, in each case that is necessary or, in the case of the AMYRIS Farnesene
Production IP, useful, to import, offer for sale and sell Licensed Products within the Territory for use in the Field;

 

(d)                                                              
a royalty-bearing (to be negotiated as described in the last sentence below), right and license under the AMYRIS Licensed
IP in each case that is necessary or, in the case of the AMYRIS Farnesene Production IP, useful to Manufacture Licensed
Products (x) within the Territory and (y) outside the Territory (subject to Section 2.E(iv) below), but, in each case, solely for
purposes of Manufacturing, importing, offering for sale, and selling such Licensed Products in the Territory for use in the Field.
The license granted under subsection (x) shall be co-exclusive with AMYRIS while the license in (y) shall be non-exclusive. Prior
to Licensed Products first being Manufactured per the license in this clause (c), TOTAL and AMYRIS will, in good faith, negotiate
commercially

    	 	10	 

    CONFIDENTIAL

    

 

reasonable terms on a “most favored
nation basis” for royalties to be paid to AMYRIS by TOTAL on the sale of such Manufactured Licensed Product in the Territory;
and

 

(e)                  
a non-exclusive, royalty-free (subject to Section 2.B below) right and license under the AMYRIS Licensed IP, in each case,
that is necessary to offer for sale, sell and import any Known By-Product(s) for any uses other than for use(s) precluded by Third
Party Conflicts; provided, however, that this license shall not expand any obligation that AMYRIS may have to disclose the AMYRIS
Licensed IP beyond what is set forth elsewhere in this Agreement. For clarity, the production of By-Products by TOTAL or its sublicensees
or Subcontractors in connection with the practice of the right to Manufacture Licensed Products pursuant to Section 2.A(d)
above shall not be a breach of this Agreement.

 

For clarity, there (i) shall be no volume or production
limits on the foregoing licenses set forth in clauses (a), (c), (d), and (e), and (ii) the licenses granted in clauses (a)-(e)
above include the right to Manufacture and, solely in the Territory for use in the Field, sell farnesane made with farnesene produced
via the exercise of such licenses.

 

(ii)            Limited License. The licenses granted TOTAL
above (a) allow it to conduct licensed activities with respect to (x) the Licensed Products solely for use in the Field and/or
(y) Known By-Products (on a case-by-case basis) solely for use outside the applicable Third Party Conflict(s), and (b) with
respect to Sections 2.A(i)(b), include the right to optimize or modify the applicable TOTAL Strain(s) by any means. Upon termination
of the license granted in Section 2.A(i)(b), unless otherwise agreed in writing by the Parties, at AMYRIS’ written request,
TOTAL shall destroy all quantities of the Intermediate Strain(s) and any Strains developed under such license based on or using
the Intermediate Strain(s) other than the Commercial Strain(s).

 

(iii)           
AMYRIS Retained Rights; TOTAL’s ROFR regarding Certain AMYRIS Manufacturing of Licensed Product in the EU. AMYRIS
retains (a) rights to Manufacture Licensed Products in the Territory but only for (1) sale within the Territory to TOTAL or its
designees and (2) use, offer for sale, and sale outside of the Territory, (b) the right to import Licensed Products into the Territory
but only for sale to TOTAL and its designees, (c) rights to Manufacture Licensed Products outside the Territory, (d) rights to
conduct activities within the Improvement Scope as permitted under the Collaboration Agreement and the conduct of the Biofene
Development Project, (e) the exclusive right to sell and offer for sale the Licensed Products outside the Territory, and (f) the
exclusive, worldwide rights to Make and Sell and otherwise exploit products for use outside the Field, including the right to
Manufacture farnesene and/or farnesane within or outside of the Territory for use in such other products. If, during the Term,
AMYRIS desires to issue an offer, or receives an offer from a Third Party, to make (or have a Third Party make) Licensed Products
in the Territory per subclause (a) above or intends on its own to begin the construction of a manufacturing facility in the Territory
to make such Licensed Products (the “Production Offer”), AMYRIS shall provide a written notice (the “Right
of First Refusal Notice”) of such Production Offer (which shall contain a copy of all relevant terms of the Production
Offer) to TOTAL. The Right of First Refusal Notice shall also

 

    	 	11	 

    CONFIDENTIAL

    

contain an irrevocable offer by Amyris to enter
into an agreement with TOTAL to participate in the construction and ownership of such facility or make such Licensed Products in
the Territory at the same price and upon terms and conditions that are no less favorable to TOTAL than those that are proposed
by Amyris or offered by a Third Party. TOTAL shall have the right and option, within sixty (60) Business Days after the date that
the Right of First Refusal Notice is delivered to accept such offer. For clarity, TOTAL’s rights in the prior sentence do
not apply to any proposed facility for the Manufacture within the Territory of farnesene and/or farnesane that will be used, within
or outside of the Territory, solely for one or more non-Licensed Product(s).

 

(iv)           
Future Licensed Product Supply Agreement. If AMYRIS is Manufacturing Licensed Product and TOTAL desires to purchase some
of such Licensed Product from AMYRIS to offer for sale and sell it for use in the Field in the Territory, the Parties will, in
good faith, negotiate commercially reasonable terms, which will include a “most favored nation basis” pricing mechanism
(based on similarity of markets, geographies, uses, quantities, etc.), for AMYRIS to supply TOTAL with agreed upon quantities
of such Licensed Product.

 

(v)General.

 

(a)                  
Survival. Except as provided in Section 2.A(i)(b) or in Section 7.C, the licenses granted to TOTAL in Article 2
shall be irrevocable until the end of the Term and remain in full force and effect during the Term, notwithstanding any breach
or alleged breach of the Collaboration Agreement or any termination or expiration of the Collaboration Agreement. For
clarity, the licenses granted to TOTAL shall terminate upon the earlier of (i) expiration of the Term and (ii) termination of this
Agreement pursuant to Section 7.C.

 

(b)                 
Licensed Patent List. The Patents existing as of the Effective Date within the AMYRIS
Licensed IP are those set forth in a letter provided by AMYRIS to TOTAL of
even date herewith. Upon TOTAL first becoming eligible to practice the license granted in Section 2.A(i)(b), AMYRIS shall provide
to TOTAL a list of Patents then currently existing within the Strain Improvement Technology. During the Term, AMYRIS shall provide
to TOTAL at least semi-annually a complete and accurate written updated list of all Patents within the AMYRIS Licensed IP and,
if TOTAL is eligible to practice the license granted in Section 2.A(i)(b), the Strain Improvement Technology; provided, however,
that such obligation shall cease (1) with respect to AMYRIS Licensed
IP as of the expiration of the last to expire of the Patents that are included in the AMYRIS Licensed IP at the time of
the first commercial sale of a Licensed Product or if no such sale has occurred by twenty (20) years after the Effective Date,
as of such date, and (2) with respect to the Strain Improvement Technology upon the existence of (x) a Suitable Commercial Strain
or (y) the achievement of a Successful Commercial Transfer of a Commercial Farnesene Strain.

 

(vi)AMYRIS Certification Materials.
If TOTAL wishes to use any AMYRIS Certification Materials to sell, as certified, a Farnesene Diesel Product for

 

    	 	12	 

    CONFIDENTIAL

    

use in the Field in the Territory, then TOTAL
shall notify AMYRIS and shall be obligated to reimburse AMYRIS for the documented amounts incurred by AMYRIS in generating the
applicable AMYRIS Certification Materials after June 21, 2010. TOTAL shall pay such amounts to AMYRIS within thirty (30) days of
receipt of an invoice therefor unless otherwise agreed in writing by the Parties.

 

(vii)Extension
of the Biofene Development Project. At any time prior to the end of the Biofene Development Project (i.e., July 31, 2016),
TOTAL may provide a written request that AMYRIS enter into negotiations regarding an extension of the Biofene Development
Project, per a Biofene Development Project Extension Agreement, with the objective of generating one or more Commercial Farnesene
Strains for use in the Field (including but not limited to Commercial Farnesene Strains with performance characteristics that exceed
the minimal requirements for Commercial Farnesene Strain). AMYRIS will have fourteen (14) days after receipt of such notice to
notify TOTAL whether it wishes to participate in such negotiations. If AMYRIS timely notifies TOTAL, the Parties will negotiate
in good faith the terms of a Biofene Development Project Extension Agreement for ninety (90) days (the “Negotiation Period
for Biofene Development Project Extension”). If AMYRIS fails to timely respond to TOTAL’s notice, Amyris declines
to participate in such negotiations, or if the Parties cannot reach agreement on the terms of such Biofene Development Project
Extension Agreement within the Negotiation Period for Biofene Development Project Extension, then TOTAL and AMYRIS have no more
obligations to attempt to extend the Biofene Development Project and in such case, but in no event before the expiration of the
Biofene Development Project, TOTAL may practice the license in Section 2.A.(b).

 

B.                
Third Party Agreements.

 

(i)           
TOTAL acknowledges that certain Patents and/or Inventions within the AMYRIS Licensed IP have been or may be licensed to AMYRIS
pursuant to one or more Third Party Agreement(s), and that the sublicenses granted by AMYRIS to TOTAL with respect to the AMYRIS
Licensed IP that is subject to any such Third Party Agreement(s) are subordinate to the applicable terms of the applicable Third
Party Agreement. In the event that such terms would impose any obligations on TOTAL beyond those set forth in this Agreement,
AMYRIS shall promptly notify TOTAL of such terms of any Third Party Agreement so that TOTAL will be informed of such terms. If
AMYRIS fails to promptly disclose any such terms, then TOTAL shall have no responsibility to comply with the non-disclosed terms
or liability for failing to so comply. In the event that the licenses granted hereunder include a sublicense under the IP License
Agreement, TOTAL acknowledges that such sublicense shall be subject to Section 2.2 thereof.

 

(ii)        
TOTAL further acknowledges that, with respect to Patents and/or Inventions within the scope of the AMYRIS Licensed IP or the Strain
Improvement Technology, as applicable, that are licensed pursuant to a Third Party Agreement to AMYRIS or its applicable Affiliate
after the completion of the Biofene Development Project, the sublicense granted by AMYRIS to TOTAL may result in payment obligations
to the Third Party for the grant and/or practice of such sublicense to TOTAL. In such a

    	 	13	 

    CONFIDENTIAL

    

 

case, TOTAL shall only receive such a sublicense
if it agrees in writing, in a form reasonably acceptable to AMYRIS, to pay any such amounts due for the grant of a sublicense to
TOTAL or practice of such a sublicense by TOTAL or its sublicensees (which payments may include milestone payments and/or royalties
on product sales), and to otherwise comply with the terms of such Third Party Agreement.

 

(iii)            In the event of the filing of a bankruptcy petition
under Title 11 of the United States Code (the “Bankruptcy Code”) by or against a licensor of intellectual property
to AMYRIS under a Third Party Agreement(s) (the “Third Party Licensor”), AMYRIS hereby assigns to TOTAL the
right to make the election set forth in Section 365(n)(1)(B) of the Bankruptcy Code (the “365(n) Election”)
if Third Party Licensor as debtor in possession, or a trustee on its behalf, rejects the Third Party Agreement pursuant to Section
365 of the Bankruptcy Code; provided, however, that such 365(n) Election must be made by TOTAL no later than the earlier of (x)
seven (7) Business Days after AMYRIS has provided written notice to TOTAL of any rejection of the Third Party Agreement and (y)
five (5) Business Days prior to any date set forth in an order of the bankruptcy court having jurisdiction over the bankruptcy
case of Third Party Licensor as the date by which any such Section 365(n) Election must be made, which deadline shall be provided
in writing to TOTAL by AMYRIS within two (2) Business Days after AMYRIS receives written notice of same from such Third Party Licensor
(the “Election Deadline”). In the event TOTAL, having received timely notice from AMYRIS of the rejection of
such Third Party Agreement, has not timely exercised the 365(n) Election by the Election Deadline, the right to make the 365(n)
Election shall transfer to JVCO, which shall have the right to exercise such 365(n) Election in accordance with the terms of the
Amended and Restated JVCO Jet Fuel License Agreement. AMYRIS shall not have the right to make the election set forth in Section
365(n)(1)(A) of the Bankruptcy Code prior to (1) the deadline established under the Amended and Restated JVCO Jet Fuel License
Agreement for JVCO to make such Section 365(n) Election, or (2) if AMYRIS fails to timely notify TOTAL of the rejection of such
Third Party Agreement, the date by which such Section 365(n) Election must be made. If neither TOTAL nor JVCO timely makes the
365(n) Election, then the right to make the Section 365(n) Election shall automatically re-vest in AMYRIS, in which case AMYRIS
shall be free to exercise the 365(n) Election in its discretion.

 

(iv)       AMYRIS agrees
not to terminate or permit termination of the Third Party Agreement containing such license by exercise of an election under Section
365(n)(1)(A) of the Bankruptcy Code without the prior written consent of TOTAL. AMYRIS acknowledges that because the sublicenses
granted by AMYRIS to TOTAL is a significant part of TOTAL’s benefits under the Agreement, TOTAL does not anticipate that
it would consent to termination of such Third Party Agreement and shall not under any circumstances be obliged to give such consent.

 

(v)      In the event that any royalties are
due under a 365(n) Election, then, for clarity, the principles of Section 2.B(ii) shall apply to the allocation of such royalties
between the Parties. For clarity, the allocation between the Parties of any royalties due

 

    	 	14	 

    CONFIDENTIAL

    

with respect to the Third Party intellectual property
subject to such 365(n) Election shall remain unaltered following such 365(n) Election.

 

C.                
Sublicenses and Subcontracts.

 

(i)            TOTAL shall have the right to grant sublicenses, through
multiple tiers, of the licenses granted to TOTAL in Section 2.A; provided, however, with respect to the Manufacture of farnesene,
TOTAL may only grant sublicenses for the Manufacture of farnesene solely for sale to TOTAL and its other sublicensees to Make and
Sell Licensed Products in the Territory in the Field. TOTAL and its Affiliates shall bind its sublicensees to the restrictions
in clauses (a) and (b) of Section 4.B(iii), and AMYRIS shall have third party beneficiary rights with respect thereto analogous
to those set forth in Section 2.C(iii)(b).

 

(ii)            TOTAL may grant to a Third Party (any such Third
Party, a “Subcontractor”) have made rights under:

 

(a)      the licenses in Section 2.A(i)(a) and (e),
as are reasonably necessary or materially useful for such Subcontractor to Manufacture the Licensed Products for TOTAL, including
without limitation, if reasonably necessary or materially useful for the relevant activity, use of the Commercial Farnesene Strain(s);
and

 

(b)      the license in Section 2.A(i)(b), on and
after the date on which such license may be practiced, as reasonably necessary or materially useful for such Subcontractor to exercise
such license for TOTAL to modify or improve the Farnesene Strain(s) for the Field.

 

Any Subcontractor
shall represent, warrant and covenant that its Manufacture and supply of farnesene or the applicable Licensed Product (or
intermediate thereof) to TOTAL will be conducted in accordance with the specifications and instructions provided by TOTAL and all
applicable Legal Requirements.

 

 (iii)            Common Provisions.

 

(a)                 Any
sublicense or Subcontractor agreement entered into by TOTAL shall be in writing and contain (1) terms that are consistent in all
material respects with this Agreement; (2) reasonable confidentiality terms that obligate the sublicensee or Subcontractor to
comply with provisions regarding non-disclosure and non-use of AMYRIS Confidential Information at least as restrictive as those
of this Agreement; (3) if the sublicensee or Subcontractor will have access to any TOTAL Strain (such a Person or any other Person
that has access to any TOTAL Strain, a “Strain Recipient”), material transfer and use restrictions on the TOTAL
Strains consistent with those as described in Section 2.E below, and, without limitation of Section 3.A, such other provisions
governing intellectual property as may be agreed in writing by TOTAL and AMYRIS, on a case-by-case basis; (4) a covenant limiting
the practice of the licenses to the Field and, as applicable, to the Territory, all as described in Section 4.B(iii) below; (5)
provisions

    	 	15	 

    CONFIDENTIAL

    

 

regarding reporting, audit and inspection
rights, including those to protect AMYRIS Farnesene Production IP and the TOTAL Strain(s), including as described in Section 2.F;
and (6) provisions to effect the transfer to TOTAL (or at the request of AMYRIS, to AMYRIS) of rights to any intellectual property
with respect to which AMYRIS is entitled to ownership, as described in Section 3.A(i) hereof).

 

(b)                 
Each sublicense or Subcontractor agreement and any other agreement that relates to use of a Strain with a Strain Recipient
shall further provide that AMYRIS shall be a third party beneficiary of such agreement by a right to directly enforce against the
sublicensee or Subcontractor or other Strain Recipient an uncured material breach of such agreement, as the case may be, if and
solely to the extent that (1) such a breach relates to activities conducted with farnesene made by a TOTAL Strain, and (2) TOTAL
fails to act reasonably and as expeditiously as possible under the circumstances to address any such breach (provided that such
failure to act expeditiously is not the result of any action or inaction on the part of AMYRIS). Each sublicensee of TOTAL hereunder
and each TOTAL Affiliate shall also be required to so designate AMYRIS as a third party beneficiary in any of its agreements with
any Strain Recipient.

 

(c)                  
Except as otherwise agreed by AMYRIS and TOTAL, each sublicensee and Subcontractor and any other Strain Recipient in any
agreement described in clause (b) above shall be required (1) to obtain and maintain insurance at least as great as required to
be held by TOTAL pursuant to Section 5.B hereof and (2) to indemnify and hold harmless AMYRIS and TOTAL and their respective directors,
officers, employees and agents from and against any and all Third Party claims, suits and proceedings to the extent that such claims,
suits and proceedings arise out of, are based on, or result from its willful misconduct or gross negligence or a breach of any
provision of Subcontractor’s or sublicensees or Strain Recipient’s agreement with TOTAL (or its Affiliates or sublicensees),
including any representation, warranty or covenant thereunder.

 

D.               
Technology Transfer and Escrow.

 

(i)            Commercial Technology Transfer. Following the
designation of a Program Strain, to facilitate the practice by TOTAL of the licenses granted herein, at TOTAL’s written request
and expense, AMYRIS shall deliver to TOTAL the Program Strain and with regard to the then current process for the Manufacture of
Licensed Products using such Program Strain and the documentation specified on Exhibit A (“Commercial Technology
Transfer Package”).

 

(ii)            Commercial Strain Technology Transfer Assistance.
At TOTAL's request and expense, to facilitate the practice of the licenses granted to TOTAL, following the designation of the first
Program Strain, AMYRIS shall provide to TOTAL (or its designee) a one-time site-specific technology transfer of the then-current
Manufacturing process for the Licensed Products using the Program Strain, which technology transfer shall include training and
on-site support (by persons directly involved in the development, use, scale-up and/or operation of the AMYRIS Licensed IP to implement
the practice of the AMYRIS Licensed IP and achieve steady state production of farnesene and/or farnesane).

    	 	16	 

    CONFIDENTIAL

    

 

(iii)            Escrow. At TOTAL’s expense, AMYRIS
will deposit (on the timing specified below) with a mutually agreed Third Party escrow agent (the “Escrow Agent”),
pursuant to one or more escrow agreements entered by such Escrow Agent, AMYRIS and TOTAL the following (collectively, the “Escrowed
Materials” and each escrowed Strain, a “Banked Strain”):

 

(a)   
Continuing until the earliest of (1) the twentieth anniversary of the Effective Date, (2) the date six (6) months after
the date on which TOTAL has the right to practice the license set forth in Section 2.A(i)(b), and (3) the achievement of a Successful
Commercial Transfer, AMYRIS shall escrow the following materials: the Intermediate Strain(s) and the then current process for the
Manufacture of Licensed Products using the Intermediate Strain(s) including the documentation specified on Exhibit B (“Initial
Package”). The Initial Package shall be escrowed no later than within ninety (90) days of the Effective Date, and at
least semi-annually thereafter until the occurrence of the earliest of clauses (1) - (3) of this Section 2.D(iii)(a), AMYRIS shall
update the Initial Package to reflect the then current process for the Manufacture of Licensed Products using the then current
Intermediate Strain(s).

 

(b)  
No later than thirty (30) days after the Parties’ designation of each Program Strain, if any, AMYRIS shall escrow
the following materials: such Program Strain and the then current process for the Manufacture of Licensed Products using such Program
Strain, including without limitation, the documentation specified on Exhibit A.

 

(c)   
TOTAL may, from time to time, obtain access to the Escrowed Materials (at the location of the Escrow Agent) for audit purposes,
i.e. to verify that the Escrowed Materials have been properly submitted and stored (provided that if AMYRIS requests, TOTAL’s
representative may be accompanied by AMYRIS’ representative during such audit), and upon request of TOTAL and at TOTAL’s
expense, AMYRIS shall cause the Escrowed Materials to be sent to an independent laboratory reasonably agreed to by the Parties
to allow testing and to evidence that the Banked Strains remain viable and continue to produce farnesene at expected yields, in
which case such laboratory shall be considered a Strain Recipient for purposes of this Agreement.

 

(d)  
TOTAL will have the right to a release of the Escrowed Materials from the Escrow Agent at such time as TOTAL is entitled
to exercise the license granted in Section 2.A(i)(b).

 

(e)   
AMYRIS’ obligations to escrow under this Agreement, including the Intermediate Strain(s), the Initial Package, and,
if applicable, the Program Strain(s) and the Commercial Technology Transfer Package, shall terminate six (6) months after the date
on which TOTAL has the right to practice the license set forth in Section 2.A(i)(b). Thereafter, TOTAL shall be responsible for
maintaining the Strains and information that were the subject of the Successful Commercial Transfer. Notwithstanding anything to
the contrary in this Agreement, under no circumstances shall TOTAL receive more than an aggregate of fourteen (14) Banked Strains.

    	 	17	 

    CONFIDENTIAL

    

 

(f)   
Any dispute between the Parties regarding the deposit of any Escrowed Materials or the access to any Escrowed Materials
shall be resolved as provided in Section 8.A, B and D.

 

(iv)           
Thirty (30) days after the date on which TOTAL has the right to practice the license set forth in Section 2.A(i)(b), AMYRIS shall
deliver to TOTAL (a) for each of the Banked Strains, detailed written (or electronic) information regarding its ancestor and lineage,
a description of each of the changes (e.g., random, rational or directed modifications) made to such strain, the types of changes
(e.g., deletion, insertion, ploidy) and the locus of each genetic modification, and (b) a family tree showing the genetic relationships
between all Strains studied or prepared in connection with the activities performed under the Collaboration Agreement, to enable
TOTAL to utilize the license granted in Section 2.A(i)(b).

 

  (v)            For clarity, the information, know-how and materials
disclosed by AMYRIS in any technology transfer or otherwise hereunder shall only be used by TOTAL and its Affiliates and sublicensees
and Subcontractors pursuant to the applicable license(s) granted in Section 2.A above and such disclosure is not intended to grant
any other rights of use, express or implied.

 

 (vi)            At the time of delivery of the Initial Package or
the Commercial Technology Transfer Package, as the case may be, Amyris shall also provide to TOTAL, upon its request, the then
current capital costs at AMYRIS’ Brotas plant and its then current operating expenses for farnesene production.

 

E.                
Strain Restrictions. During the Term except as expressly provided in this Agreement (e.g., Section 2.A(i)(b)),
without the express written consent of AMYRIS, TOTAL shall:

 

(i)           
not, and shall not allow any other Person to, (a) engage in the further optimization of any Commercial Farnesene Strain(s), including
using any strain engineering or method of genetic manipulation by any means other than random mutagenesis, and (b) use any other
TOTAL Strain other than pursuant to the license set forth in Section 2.A(i)(b), if applicable;

 

(ii)            not, and shall not allow any other Person to, except
as expressly permitted in this Agreement, (a) reverse engineer any TOTAL Strain(s), (b) engineer any other strain from the Commercial
Farnesene Strain(s) (c) use any TOTAL Strain, or (d) distribute, disclose or transfer any TOTAL Strain, or any AMYRIS Licensed
IP, with respect to subsections (a) and (b) of this Section 2.E(ii), for any purpose; and with respect to subsections (c) and (d)
of this Section 2.E(ii), for any purpose outside of the scope of licenses granted in Section 2.A above and the subcontracting rights
set forth in Section 2.C, and in all such cases, such activities shall be subject to the terms of this Agreement;

 

  (iii)         handle, and cause any Strain Recipient to handle, the TOTAL Strain(s)
in a safe and prudent manner, in accordance with applicable law and regulations

    	 	18	 

    CONFIDENTIAL

    

 

and guidelines used by AMYRIS in its own activities
involving the TOTAL Strains, as provided by AMYRIS to TOTAL;

 

(iv)            not distribute, disclose or transfer (or permit to
be distributed, disclosed or transferred) the Intermediate Strain(s) or any other Strain that is a genetic manipulation or modification
of any Intermediate Strain (other than the Commercial Farnesene Strain(s) which TOTAL may use as described below) in connection
with the exercise of its license under Section 2.A(i)(b), if applicable, to any other Person (except pursuant to and in accordance
this Agreement) or to any location other than the following countries: Australia, Brazil, Canada, Japan, Mexico, South Korea, United
States, or the countries of the Territory. For clarity, it is understood and agreed that TOTAL and its designees may conduct any
licensed activities involving the practice of the licenses granted to TOTAL under Section 2.A(i)(a), (d), (e), or (f) (e.g.
use of a Commercial Farnesene Strain for production of Licensed Products as well as any downstream processing of Licensed Products)
in any location such entities deem appropriate; provided, if TOTAL or its designees intend to conduct the Manufacture of farnesene
in any country other than: Australia, Brazil, Canada, Japan, Mexico, South Korea, United States and the countries of Territory,
TOTAL shall notify AMYRIS at least sixty (60) days prior to the selection of the applicable country as a farnesene manufacturing
location. If AMYRIS believes that the farnesene Manufacture in such identified country would pose material risk that the conduct
of such activities could jeopardize any Commercial Farnesene Strain, including loss of trade secret status with respect to the
Commercial Farnesene Strain or any material information with respect thereto or to the related manufacturing process, AMYRIS shall
identify such risks with particularity and provide reasonable evidence that the existing precautionary measures provided in this
Agreement are insufficient with respect to such material risks. In any such case, the Parties shall discuss in good faith such
risks and other reasonable precautionary measures that could be taken to mitigate such risks. In the event the Parties agree on
such other precautionary measures, then such measures shall constitute the “Precautionary Measures”. In the
event the Parties do not agree on whether any Precautionary Measures should be established or the nature of such Precautionary
Measures, either Party may refer the matter to the dispute resolution procedures under Sections 8.A and 8.B for determination of
(a) whether any Precautionary Measures should be established and (b) if so, the nature of such Precautionary Measures. TOTAL shall
implement any Precautionary Measures (whether mutually agreed or established pursuant to the preceding sentence) prior to engaging
in the licensed activities in the applicable country and shall maintain any such Precautionary Measures in place for so long as
such activities are being conducted;

 

(v)            ensure that any sublicensee, Subcontractor or Strain
Recipient shall be expressly bound in writing to the provisions set forth in this Section 2.E; and

 

(vi)             With regard to TOTAL’s exercise
of its license in Section 2.A(i)(b), the terms in this Section 2.E supersede any and all limitations on TOTAL’s ability
to modify or optimize the Farnesene Strain(s) using only random mutagenesis that are contained in other contracts between the Parties,
including without limitation, those set

 

    	 	19	 

    CONFIDENTIAL

    

forth in Section 6.2(c) or 6.3(a) of the Collaboration
Agreement or paragraph 13 of the Second Amendment to the Collaboration Agreement.

 

F.                 
Reporting, Audit and Inspection Rights. This Section 2.F shall apply to any Third Party that Manufactures farnesene
for TOTAL (each a “Third Party Manufacturer”) or, if TOTAL Manufactures Licensed Products itself, to TOTAL and
to any other Strain Recipient. AMYRIS shall have the right, upon reasonable prior notice and during normal business hours, at agreed
times to inspect those portions of facilities at which farnesene is Manufactured or where any TOTAL Strain is used where such activities
occur, and the books and records of Third Party Manufacturer or TOTAL or other Strain Recipient, as applicable, relating specifically
to such Manufacture or any TOTAL Strain, including any Manufacturing batch records for the Manufacture of farnesene. At the request
of any Third Party Manufacturer, AMYRIS shall enter into a customary confidentiality agreement with the Third Party Manufacturer
in form and substance reasonably acceptable to the Manufacturer to keep the results of such inspection confidential, provided that
AMYRIS may (i) share with TOTAL the results of any such inspections, and (ii) use and disclose such results to the extent reasonably
necessary to enable TOTAL to enforce its rights under its contract with the Third Party Manufacturer. TOTAL or any Third Party
Manufacturer, as applicable, shall deliver to AMYRIS a once-monthly summary report relating to any Manufacture conducted using
any TOTAL Strain and such other customarily-maintained information regarding such Manufacture as may be reasonably requested by
AMYRIS.

 

G.               
No Implied Rights. For the avoidance of doubt, (i) TOTAL and its Affiliates shall have no right, express or
implied, with respect to any intellectual property rights of AMYRIS or any of its Affiliates, except as expressly provided in this
Agreement or the Collaboration Agreement and (ii) AMYRIS and its Affiliates shall have no right, express or implied, with
respect to any intellectual property rights of TOTAL or any of its Affiliates, except as expressly provided in this Agreement or
the Collaboration Agreement.

 

H.               
By-Products. 

 

(i) As used in this Section, “Third
Party Conflict” is a conflict between (a) a proposed grant of a non-exclusive license to TOTAL under Section 2.A(i)(e)
with respect to a potential Known By-Product or Known By-Product and (b) a written agreement between AMYRIS and a Third Party granting
an exclusive license or other exclusive commercial rights (e.g. non-competition) to such Third Party for the applicable potential
Known By-Product or Known By-Product for one or more uses, which contractual right is in effect at the time of designation of the
applicable By-Product as a Known By-Product, which written agreement either (x) precludes designating such By-Product as a
Known By-Product for any uses, or (y) excludes one or more uses from TOTAL’s non-exclusive license for such Known By-Product(s)
for one or more specific uses (including the making of a particular Known By-Product from a non-conflicting By-Product and using
such Known By-Product for one or more specific excluded uses). In the event that a Third Party Conflict exists for some but not
all uses for a particular Known By-Product, the Third Party Conflict shall only apply to these limited uses.

    	 	20	 

    CONFIDENTIAL

    

 

(ii)As used
in this Section, a “Potential Third Party Conflict” is a conflict between (a) a proposed grant of a non-exclusive
license to TOTAL under Section 2.A(i)(e) with respect to any potential Known By-Product or Known By-Product, and (b) any
arrangement that AMYRIS is negotiating in good faith with a Third Party pursuant to a written term sheet in which AMYRIS has offered
to grant an exclusive license or other exclusive commercial rights (e.g. non competition) with regard to any such By-Products for
one or more uses, and timely notified TOTAL pursuant to Section 2.H(iii) below, provided that such term sheet (whether or not binding)
either (x) precludes designating such By-Product as a Known By-Product or (y) specifically excludes one or more uses from
TOTAL’s non-exclusive license for such Known By-Product(s) (including the making of a particular Known By-Product from a
non-conflicting By-Product and using such Known By-product for one or more specific excluded uses). If there is a Potential Third
Party Conflict, the applicable By-Product shall not be designated as a Known By-Product (or in the case of a Known By-Product as
of the Effective Date, shall be suspended unless and until the first to occur of: (a) AMYRIS ceases such negotiations, or (b) AMYRIS
has not completed such negotiations with the Third Party with which it was negotiating as of the date of AMYRIS’ notice of
the Potential Third Party Conflict within twelve (12) months after such receipt or delivery of notice (the “Negotiation
Period”). If AMYRIS timely concludes such negotiations and enters a definitive agreement with such Third Party, then
the Potential Third Party Conflict with respect such agreement would become a Third Party Conflict. In the event that a Third Party
Conflict exists for some but not all uses for a particular Known By-Product, the Third Party Conflict shall only apply to these
limited uses.

 

(iii)  Within
three (3) weeks after the Effective Date, AMYRIS shall notify TOTAL of all Third Party Conflicts with respect to the Known
By-Products identified as of the Effective Date and Total, on the behalf of TOTAL, may, at its election, initiate the verification
process as provided for in Section 2.H.(vii). With respect to Known By-Products identified as of the Effective Date, AMYRIS
shall not enter into any term sheet that would conflict with the rights granted to TOTAL hereunder and/or any exclusive agreement
with any Third Party after the Effective Date.

 

(iv)During the
Term of this Agreement, if (x) AMYRIS in the course of performing the Biofene Development Project or (y) TOTAL identifies
any By-Products that are not then Known By-Products, it shall notify the other Party in writing and identify such By-Product (by
chemical structure, if possible, and if not, by some other unambiguous manner of characterization) and prevalence relative to the
Licensed Product. Upon receipt of such notice, such By-Product shall be designated as a Known By-Product (and listed on Exhibit
D) unless, within forty-five (45) days of AMYRIS’ receipt or delivery of such notice, AMYRIS notifies TOTAL of a Third
Party Conflict(s) with respect to such By-Product that prevents such By-Product from being designated as a Known By-Product, in
which case such By-Product will not be designated as a Known By-Product, except as otherwise provided in this Section 2.H.

 

(v) If AMYRIS fails to identify a Third Party
Conflict or Potential Third Party Conflict within the applicable time frame set forth above, with respect to (a) a

    	 	21	 

    CONFIDENTIAL

    

 

particular potential Known By-Product, then such
potential Known By-Product shall be a Known By-Product and automatically be listed on Exhibit D hereto, and (b) a Known
By-Product, then any such unidentified Third Party Conflict shall not limit TOTAL’s non-exclusive license hereunder with
regard thereto.

 

(vi) If at any time a Potential Third Party Conflict
and/or a Third Party Conflict, as applicable, that previously existed has, in part or in whole, been reduced or eliminated for
one or more Known By-Products or for any By-Product denied designation as a Known By-Product, AMYRIS will within thirty (30) days
notify TOTAL in writing, identifying for each By-Product all remaining limitations on such use, and the list of Third Party Conflict(s)
will, with regard to such affected By-Products, be automatically modified accordingly.

 

(vii)In
the event that TOTAL desires verification of the scope or applicability of any Third Party Conflict with respect to any particular
Known By-Product or By-Product denied designation as a Known By-Product, then on or after receipt of notice of the applicable Third
Party Conflict, TOTAL shall notify AMYRIS in writing, and AMYRIS shall make available a copy of all terms of the agreement(s) entered
by AMYRIS with Third Parties, which terms give rise to the Third Party Conflict(s) at issue, and any ancillary provisions necessary
to fully interpret such Third Party Conflict(s), to a mutually acceptable, conflict-free attorney practicing in the United States
at a nationally recognized law firm and who has an college or advanced degree in chemistry for the sole purpose of determining
whether AMYRIS has accurately described the scope or applicability of the license grant or other restrictions that comprise the
Third Party Conflict(s) with regard to the applicable Known By-Product or By-Product denied designation as a Known By-Product so
that TOTAL can be informed of the information described in the following sentence. Subject to obligations of confidentiality to
AMYRIS, such attorney may disclose to TOTAL, with respect to any particular Known By-Product or By-Product denied designation as
a Known By-Product, the scope of the license(s) and applicable restrictions (including, the uses, geographies and time periods)
comprising the Third Party Conflict under the applicable Third Party agreement, but not the provisions themselves. The costs of
any such determination shall be borne by TOTAL (or its designee).

 

(viii)In the event that there are limits on
the ability of TOTAL to commercialize a particular Known By-Product or By-Product denied designation as a Known By-Product due
to Third Party agreements previously entered by AMYRIS, at the request of TOTAL, AMYRIS and TOTAL shall discuss in good faith structures
and, if possible, terms for the commercialization of such Known By-Product or By-Product denied designation as a Known By-Product,
consistent with AMYRIS’ existing obligations to Third Parties.

 

I.                  
License to AMYRIS. Subject to the terms of this Section 2.I, TOTAL hereby grants to AMYRIS a non-exclusive, worldwide,
sublicensable, fully-paid up, royalty-free right and license under the TOTAL Independent Strain Engineering Patents to develop
Strains to Make and Sell isoprenoids except farnesene for use in or as Jet Products; however, the license with respect to Diesel
Products shall be subject to the limitations in

    	 	22	 

    CONFIDENTIAL

    

 

Section 2.A(iii). The license granted to AMYRIS
herein may not be terminated other than as specified in this Section. In the case of a material breach (but only in the case of
a material breach) of the relevant license, TOTAL shall have the right to terminate the license in accordance with the following.
If TOTAL believes any such breach by AMYRIS has occurred, TOTAL shall within thirty (30) days provide written notice to AMYRIS
describing the specific alleged material breach. If a material breach is not cured within sixty (60) days of AMYRIS’s receipt
of such notice, then TOTAL may terminate the applicable license with further written notice to AMYRIS (A) immediately at the end
of such sixty (60) day period, if AMYRIS has not contested the allegation, or (B) if AMYRIS has contested such allegation, only
upon a final written determination, if any, of an arbitrator in a proceeding subject to Section 8.B that an uncured material breach
has occurred. For clarity, in the case of any dispute between the Parties as to whether any uncured material breach has occurred
that would permit TOTAL to terminate the license, no notice of termination may be given and no such termination shall be effective
until the final resolution of a dispute resolution proceeding conducted pursuant to Section 8.B, and such license may only be terminated
if the arbitrator finally determines an uncured material breach has occurred. For purposes of determining whether a material breach
that would trigger a right of termination under Section has occurred, any Affiliate of AMYRIS shall be treated as if it was
AMYRIS.

 

In the event that any subcontractor or sublicensee
of AMYRIS violates this Section, then such violation may provide a basis for a material breach and termination of this license,
but only if AMYRIS fails to use commercially reasonable efforts to cure such breach, which efforts may include terminating its
agreement with such subcontractor or sublicensee and initiating and continuing to pursue appropriate legal action to stop such
unauthorized activity. Unless terminated as set forth in this Section, the foregoing license shall remain in effect after a termination
of this Agreement by AMYRIS under Article 7.C. Each agreement in which AMYRIS grants a sublicense under, or authorizes a subcontractor
to practice, any TOTAL Independent Strain Engineering Patents shall require such subcontactor or sublicensee to agree that TOTAL
shall be an intended third party beneficiary of such agreement with a right to directly enforce against the sublicensee or subcontractor
any uncured material breach of such agreement, to the extent that (1) such a breach relates to a breach of the scope of the sublicense
under the TOTAL Independent Strain Engineering Patents and (2) AMYRIS fails to act reasonably to remedy any such breach. In all
cases, TOTAL shall have the rights to seek any remedies available at law or in equity for any breach.

 

Article
3.   OWNERSHIP AND PATENT MATTERS

 

A.               
Ownership.

 

(i)            Biofene Development Project and Collaboration Agreement
Inventions.  TOTAL and AMYRIS agree that the ownership of, and rights to, any and all Inventions developed, conceived,
or reduced to practice in whole or in part by AMYRIS and/or TOTAL in the performance of the Biofene Development Project or the
Collaboration Agreement shall be governed by Section 6.1(d) of the Collaboration

    	 	23	 

    CONFIDENTIAL

    

 

Agreement.

 

(ii)            TOTAL Inventions. Unless otherwise agreed
in writing by the Parties, TOTAL shall be the sole owner of any Inventions that are conceived and reduced to practice by TOTAL
or its Affiliates, subcontractors, or Sublicensees, including any conceived and reduced to practice by TOTAL or its Affiliates,
subcontractors, or Sublicensees in the practice of the licenses in Section 2.A(i), and any such Invention shall be TOTAL Non-Collaboration
IP.  For clarity, (a) Inventions conceived and reduced to practice by TOTAL or its Affiliates, subcontractors, or Sublicensees
in the practice of the licenses in Section 2.A(i) shall not be governed by Section 6.1(d) of the Collaboration Agreement; and (b)
notwithstanding the license from TOTAL under Section 2.I, AMYRIS (and its Affiliates and sublicensees of such license) shall not
by virtue of such license be considered as Sublicensees of TOTAL.

 

B.                
Prosecution and Maintenance of Patents.  

 

(i)            Collaboration Agreement. TOTAL agrees that
with respect to the Inventions deemed to be Collaboration IP pursuant to 3.A(i) above, the patent prosecution and maintenance provisions
of Section 6.8 of the Collaboration Agreement apply with respect to any Patents filed with respect thereto. 

 

(ii)            Patent Maintenance. AMYRIS shall comply with
the terms of Section 4.D(i) below.

 

(iii)            TOTAL-Owned Patents. TOTAL shall at its discretion
and expense, conduct and be responsible for the prosecution and maintenance of patent applications it files with respect to Inventions
owned by it pursuant to Section 3.A(ii) above.

 

C.                
Information Rights. To the extent that TOTAL would not already be entitled to the following reports and information
pursuant to the Collaboration Agreement, then:

 

(i)            Status Reports. AMYRIS shall provide to TOTAL
at least quarterly, or on such other schedule as the Parties may agree, a status report on the prosecution and maintenance of patent
applications and patents within the AMYRIS Licensed IP. In addition, AMYRIS shall provide TOTAL with periodic updates regarding
Inventions (including intellectual property) generated in connection with the Biofene Development Project and/or that specifically
relate to Licensed Products, decisions to file (or not file) patent applications with respect to such Inventions, and the status
of any patent applications filed with respect to such Inventions.

 

(ii)            Review Rights. To allow TOTAL to be informed
with respect to AMYRIS Licensed IP licensed to TOTAL under this Agreement, TOTAL shall have the right, on reasonable notice, to
inspect and review the following records maintained by AMYRIS relating to the information contained in those certain Biofene Development
Project weekly reports and quarterly reports provided under the Collaboration Agreement and the associated documentation forming
the basis of such reports, including at least,

    	 	24	 

    CONFIDENTIAL

    

 

standard operating
protocols, procedures, batch records, reports regarding deviations, laboratory notes, bioinformatic and genomic data, detailed
fermentation performance data in the laboratory, pilot plant or manufacturing runs, in each case, solely to the extent necessary
(or in the case of the AMYRIS Farnesene Production IP included therein, materially useful) for TOTAL (or its sublicensees
or Subcontractors) to exercise its rights or perform its obligations under this Agreement and, for clarity, provided that AMYRIS
shall not be required to create any documents not already in existence for the sole purpose of complying with this clause 3.C(ii).

 

D.               
Patent Enforcement.

 

(i)            Notice. Each of AMYRIS and TOTAL shall promptly
notify the other in writing of any existing or threatened infringement or misappropriation by any Third Party of any AMYRIS Licensed
IP licensed to TOTAL under this Agreement, which infringement or misappropriation could reasonably be expected to have a material
adverse effect on the ability of TOTAL or its designees to Make and/or Sell one or more Licensed Products in the Field in the Territory
(“Infringement”) of which it becomes aware, and upon reasonable request (and subject to an applicable common
interest agreement) shall provide all evidence in its possession demonstrating such Infringement (other than information that such
Party is prevented from disclosing due to confidentiality or other similar obligations). 

 

(ii)           
Collaboration Agreement. The Parties agree that the patent enforcement provisions of Section 7.2 of the Collaboration
Agreement shall govern any intellectual property that is the subject thereof and agree to be bound by such provisions, except
as expressly provided below.

 

(a)                  
AMYRIS. AMYRIS shall have the first right (but not the obligation) to enforce any issued Patent(s) within the AMYRIS
Licensed IP claiming the use of any Licensed Product(s) in the Field in the Territory, including without limitation European Patent
application EP 2084249, against any Third Party infringement (including any declaratory judgment with respect to Third Party non-infringement)
that would adversely affect the business of TOTAL relating to Licensed Products in the Field in the Territory and to conduct the
defense in connection with any such action. At the request of AMYRIS or TOTAL, TOTAL and AMYRIS shall discuss means to cease any
such infringement. If AMYRIS fails to commence a proceeding to cease any such infringement within one hundred twenty (120) days
of becoming aware of such an infringement, TOTAL shall have the right to commence and control proceedings to cease any such infringement.
In each case, the enforcing Party may retain any damages recovered in any such proceeding. In any enforcement proceeding that is
the subject of this Section 3.D(ii)(a), TOTAL (and its Affiliates and sublicensees) or AMYRIS, as the case may be, shall
join in any such proceeding, at the enforcing Party's request or if required by applicable law, in each case at the enforcing Party’s
expense. In a case in which TOTAL is enforcing under this Section 3.D(ii)(a), AMYRIS and TOTAL shall seek to develop a litigation
strategy that will cease the infringement while limiting any adverse impact on the other businesses of AMYRIS or any of its Affiliates
or licensees.

    	 	25	 

    CONFIDENTIAL

    

 

(b)                 
TOTAL. For any Patents or other intellectual property owned by TOTAL, TOTAL shall have the sole right, at its expense,
to enforce and defend such Patents or other intellectual property (including without limitation, any declaratory judgment actions)
and to retain any recovery.

 

(c)                  
Cooperation. In connection with any claim, suit or proceeding subject to this Section 3.D (including per Section
7.2 of the Collaboration Agreement), the Parties shall cooperate with each other (in the case of enforcement by TOTAL, at the expense
of TOTAL) and shall keep each other reasonably informed of all material developments in connection with any such claim, suit or
proceeding.

 

(d)                 
Settlement. In connection with any claim, suit or proceeding subject to this Section 3.D(ii), neither Party
shall enter into any settlement agreement with any Third Party that would conflict with rights granted to the other Party under
this Agreement, or impose any obligations on such other Party (beyond those already included herein), without the prior written
consent of such affected Party, which consent shall not be unreasonably withheld.

 

E.                
Infringement of Third Party Rights.

 

(i)            If a Licensed Product becomes the subject of a claim
or assertion of infringement of a Third Party Patent granted in any jurisdiction, the Party first learning of such claim or assertion
shall promptly notify the other Party in writing, and shall provide all information relating thereto (other than information that
such Party is prevented from disclosing due to confidentiality or other similar obligations).

 

 (ii)            In the event of such a Third Party claim of infringement,
any Party that is the subject of such claim or assertion under this Section 3.E may defend itself in its sole discretion and
at its sole expense; provided, however, that (a) the Party that is the indemnifying Party with respect to such claim pursuant to
the terms of Section 5 or (b) the Party designated in writing by the Parties may control the conduct of any proceeding and
in such case the procedures set forth in Section 5.A shall govern the defense of such action. In any such case, the Indemnified
Party shall cooperate with the Indemnifying Party with such defense; provided, if there is a conflict of interest between the Parties,
the Indemnified Party shall be entitled to be represented by separate counsel at the Indemnifying Party’s expense. In a case
in which TOTAL is defending an action under this Section 3.E(ii)(b), AMYRIS and TOTAL shall seek to develop a litigation strategy
to defend the claim while limiting any adverse impact on the other businesses of AMYRIS or any of its Affiliates or other licensees.

 

 
(iii)            In connection with any such claim of infringement,
TOTAL and AMYRIS shall cooperate in the defense of any such action at the request and expense of the Party controlling such action,
unless there is a material conflict of interest that would prevent such cooperation.

    	 	26	 

    CONFIDENTIAL

    

 

 (iv)            In connection with any claim, suit or proceeding
that is the subject of this Section 3.E, neither Party shall enter into any settlement agreement with any Third Party that would
conflict with rights granted to the other Party under this Agreement, or impose any obligations on such other Party (beyond those
already included herein), without the prior written consent of such affected Party, which consent shall not be unreasonably withheld.

 

F.                 
Common Interest Disclosures and Agreement. With regard to any information, materials or opinions disclosed relating
to the freedom to operate under the licenses granted hereunder, which information, materials or opinions are regarding intellectual
property or technology owned by Third Parties that may affect the conduct of TOTAL and the activities contemplated by this Agreement,
the Parties agree that they have a common legal interest in determining whether, and to what extent, such Third Party intellectual
property rights may affect the conduct of TOTAL and the activities contemplated by this Agreement, and have a further common legal
interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual
property rights relating to TOTAL. All such information, materials and opinions will be treated if applicable as protected by the
attorney-client privilege, the work product privilege, and any other privilege or immunity from discovery that may otherwise be
applicable. By sharing any such information, materials or opinions, neither Party intends to waive or limit any privilege or immunity
from discovery that may apply to the shared information and materials. Neither Party shall have the authority to waive any privilege
or immunity on behalf of the other Party without such other Party’s prior written consent, nor shall the waiver of privilege
or immunity resulting from the conduct of one Party be deemed to apply against the other Party. With regard to the prosecution
of Patents for intellectual property governed by the Collaboration Agreement, the Parties have executed a Common Interest Agreement.
For other relevant matters, the Parties shall enter into a reasonable common interest agreement, with the consent to the terms
not to be unreasonably withheld.

 

Article
4.   REPRESENTATIONS, WARRANTIES AND COVENANTS

 

A.               
Mutual Representations and Warranties. TOTAL hereby makes the following representations and warranties to AMYRIS,
and AMYRIS hereby makes the following representations and warranties to TOTAL, in each case as of the Effective Date:

 

(i)            It is a company duly organized, validly existing and
in good standing under the laws of the jurisdiction in which it is organized. It has all requisite corporate power and authority
to own its respective properties and to carry on its respective business as conducted as of the date of this Agreement and as proposed
to be conducted. It has the requisite power and authority to execute, deliver and perform its obligations under this Agreement.

 

(ii)            All corporate action on the part of it, its officers,
directors and stockholders necessary for the authorization, execution and delivery of this Agreement, and the performance of all
obligations hereunder, has been taken or shall be taken prior to the

    	 	27	 

    CONFIDENTIAL

    

 

date of this Agreement, and this Agreement, when
executed and delivered by it, shall constitute a valid and legally binding obligation of it, enforceable against it in accordance
with its terms except to the extent that (a) such enforcement may be subject to bankruptcy, insolvency, reorganization, moratorium
or other similar laws now or hereafter in effect relating to creditor’s rights generally and (b) the remedy of specific performance
or injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before
which any proceeding therefor may be brought.

 

(iii)            The execution, delivery and performance of this
Agreement (with or without the giving of notice, the lapse of time or both) and the consummation of the transactions contemplated
hereby, (a) do not require the consent of any Third Party; (b) do not conflict with, result in a breach of, or constitute a default
under, its organizational documents or any other material contract or agreement to which it is a party or by which it may be bound
or affected; and (c) do not violate in any material respect any provision of applicable law or any order, injunction, judgment
or decree of any Governmental Entity by which it may be bound, or require any regulatory filings or other actions to comply with
the requirements of applicable law, except to the extent that either Party is required to file any notification pursuant to applicable
anti-trust or competition laws. It is not a party to, nor is it bound by, any agreement or commitment that prohibits the execution
and delivery of this Agreement.

 

(iv)            No insolvency proceedings of any character, including
bankruptcy, receivership, reorganization, composition or arrangement with creditors, voluntary or involuntary, affecting it are
pending or threatened, and it has not made any assignment for the benefit of creditors or taken any action in contemplation of,
or which would constitute the basis for, the institution of such insolvency proceedings.

 

(v)            There is no action, suit, proceeding or investigation
pending or threatened against it which questions the validity of this Agreement. It is not in violation of any applicable law in
respect of the conduct of its business or the ownership of its properties which violation would have a material adverse effect
on its business or the ownership of its properties, and it shall undertake its obligations hereunder in accordance in all material
respects with applicable law.

 

B.                
Covenants of TOTAL. During the Term:

 

 (i)            TOTAL and its Affiliates shall have valid arrangements
with all of its Subcontractors, consultants and employees that are enforceable in accordance with its terms, except as enforcement
may be limited or affected by applicable bankruptcy, insolvency, moratorium, reorganization or other laws of general application
relating to or affecting creditors’ rights generally, and are sufficient to assign all of their rights, title and interest
in and to all Inventions or other technology or intellectual property developed or created by them in connection with this Agreement
to TOTAL or its Affiliates, as applicable, in order to effect the ownership principles set forth in Section 3.A.

    	 	28	 

    CONFIDENTIAL

    

 

(ii)            TOTAL shall not enter into any agreement, contract,
lease, license, instrument or other arrangement with a Third Party that results in a breach of or constitutes a default under this
Agreement.

 

(iii)            TOTAL and its Affiliates, Subcontractors, and sublicensees
shall not (a) exercise the licenses granted in Section 2.A outside the Field or (b) knowingly sell Licensed Products to customers
for any use outside the Territory or for any use within the Territory that is outside the Field.

 

(iv)            TOTAL shall not, and shall use reasonable efforts
to ensure that its Affiliates, Subcontractors, sublicensees and customers do not, use or sell any Licensed Product for any
use outside the Territory or for any use within the Territory that is outside the Field.

 

C.                
Representations and Warranties of AMYRIS. AMYRIS represents and warrants, as of the Effective Date, that:

 

(i)            AMYRIS and/or its Affiliates (a) owns and possesses
sufficient right, title and interest in the AMYRIS Licensed IP to grant the rights granted herein, (b) has a valid and enforceable
written license to the AMYRIS Licensed IP that includes the right to sublicense to the extent of the licenses granted herein and/or
(c) has obtained all necessary consents of any Third Party required, for AMYRIS and/or any of its Affiliates to grant the licenses
and sublicenses to TOTAL with respect to the AMYRIS Licensed IP granted herein.

 

(ii)            The non-financial terms of this Agreement are no
less favorable than those licenses that AMYRIS grants to other partners for the Manufacture of farnesene and/or farnesane.

 

(iii)            AMYRIS has provided to TOTAL an accurate and complete
list of all existing agreements between AMYRIS (and/or its Affiliates) and Third Parties that provide to AMYRIS (and/or its Affiliates)
licenses or other rights to AMYRIS Licensed IP that AMYRIS believes may be necessary for the practice of the AMYRIS Licensed IP
by TOTAL with respect to the Licensed Products under the licenses granted in Section 2.A(i)(a), (c), and (d), and has disclosed
to TOTAL all terms in such agreements that would impose any obligations on TOTAL beyond those set forth in this Agreement.

 

(iv)            The AMYRIS Licensed IP is subject to no Liens and/or
other restrictions and/or limitations, in each case which would prevent the grant to TOTAL of the licenses set forth herein on
the terms and conditions set forth herein, and neither AMYRIS nor any of its Affiliates has granted any Third Party any rights
under the AMYRIS Licensed IP or the Strain Improvement Technology in the Field that would conflict with the licenses granted to
TOTAL herein.

 

(v)            Neither AMYRIS nor any of its Affiliates is in material
breach of any of its agreements with Third Parties and no Third Party has notified AMYRIS and/or

    	 	29	 

    CONFIDENTIAL

    

 

any of its Affiliates of any material breach of
such Third Party Agreement(s), in each case that remains uncured and which would result in a material adverse effect on the ability
of AMYRIS and/or its Affiliates to perform its obligations hereunder. AMYRIS and/or its Affiliates have not received written notice
from any licensor under a Third Party Agreement purporting to terminate, and/or restrict the scope of, AMYRIS' rights under such
Third Party Agreement by reason of any action and/or omission of AMYRIS and/or its Affiliates.

 

(vi)            Except as provided by AMYRIS to TOTAL prior to the
Effective Date, AMYRIS and its Affiliates (a) have not received any communications alleging that any use of the AMYRIS Licensed
IP by AMYRIS or any of its Affiliates has violated, infringed or misappropriated or would violate, infringe or misappropriate any
of the intellectual property of any other person or entity and (b) has no Knowledge of any Third Party infringement, misappropriation
or violation of any AMYRIS Licensed IP.  

 

(vii)            To its Knowledge, there are no pending or issued
patent rights of any Third Party that foreclose practice of any AMYRIS Licensed IP for the following purposes: (a) to make farnesene
using the Mevalonate Pathway or (b) to Make and Sell Licensed Products.

 

 (viii)            Novvi, per Section 5.2 of the IP License Agreement,
has (a) agreed that AMYRIS and/or its Affiliates solely and exclusively own the AMYRIS Biofene Manufacturing Technology and (b)
has assigned exclusively to AMYRIS all rights, title, and interest in and to any and all inventions, discoveries, data and information,
whether or not copyrightable or patentable, conceived, reduced to practice, made, observed or developed (together with all intellectual
property rights related thereto) by or on behalf of Novvi or its Affiliates or sublicensees, solely or jointly with others, or
jointly by or on behalf of AMYRIS and Novvi (or their respective Affiliates, employees, sublicensees, contractors, or agents),
in each case that are based upon, derived from, incorporating, in connection with, or related to the Amyris Biofene Manufacturing
Technology. The “AMYRIS Biofene Manufacturing Technology” are patents and know-how that are controlled by AMYRIS
and are necessary or reasonably useful for the development, making (and having made), offering for sale, sale, and importing of
farnesene itself, including, but not limited to, Farnesene Strains and any patents and know-how related to the genetic engineering
of such Farnesene Strains, the fermentation methods for making farnesene, the methods of recovery of farnesene from fermentation
broth, the processes of isolating farnesene directly from fermentation broth, and the methods of purifying farnesene.

 

(ix)            Except as provided by AMYRIS to TOTAL prior to the
Effective Date, to AMYRIS’s Knowledge: (a) there is no claim by any Person contesting the validity and/or enforceability
of the Patents within the AMYRIS Licensed IP, and/or use and/or ownership of the AMYRIS Licensed IP, is currently outstanding and/or
threatened, and (b) there is no pending (i.e., filed and/or requested) interference and/or litigation that involves any of the
Patents within the AMYRIS Licensed IP licensed hereunder.

    	 	30	 

    CONFIDENTIAL

    

 

D.               
AMYRIS' Covenants. AMYRIS hereby covenants that during the Term:

 

(i)            AMYRIS and its Affiliates shall timely pay all maintenance
costs, annuity payments and similar fees due with respect to all Patents within the AMYRIS Licensed IP issued in the following
countries: United States, Europe (in any country(ies) where any European Patent was validated), Brazil, Canada, China, India, and
Japan. AMYRIS shall notify TOTAL prior to abandoning any other issued Patents within the AMYRIS Licensed IP with respect to which
TOTAL has an enforcement right pursuant to Section 3.D and afford TOTAL an opportunity to pay the maintenance fees and annuity
payments associated with such Patents, and if TOTAL makes such payments, AMYRIS and each of its Affiliates shall promptly assign
to TOTAL its entire right, title and interest in such Patent. To the extent that AMYRIS has an obligation to assign a Patent to
TOTAL under this paragraph and also to assign the same Patent to JVCO under the Amended and Restated JVCO Jet Fuel Agreement, AMYRIS’
obligations under this Agreement shall take precedence. AMYRIS shall notify TOTAL if any Patents within the AMYRIS Licensed IP
become subject to an interference, reissue, or re-examination. In such event, if AMYRIS elects not to undertake commercially reasonable
efforts to respond to such interference, reissue or re-examination and defend the claims at issue, then it shall notify TOTAL and
afford TOTAL the right to respond thereto. Notwithstanding the foregoing, TOTAL’s rights with respect to prosecution under
this clause (i) shall apply with respect to in-licensed AMYRIS Licensed IP only to the extent that AMYRIS has the right to afford
TOTAL such rights, e.g., AMYRIS controls prosecution of the applicable patent applications or patent rights under the applicable
license agreement. To the extent that AMYRIS has an obligation to allow TOTAL to respond to an interference, reissue or re-examination
under this paragraph and also to allow JVCO to respond to the same interference, reissue or re-examination under the Amended and
Restated JVCO Jet Fuel Agreement, AMYRIS’ obligations under this Agreement shall take precedence.

 

(ii)            For so long as any Third Party Agreement is necessary
or materially useful for TOTAL to Make and Sell the Licensed Products in the Field in the Territory using a Commercial Farnesene
Strain (“Subject Third Party Agreement”), (a) with respect to Subject Third Party Agreements that are necessary
for TOTAL to practice the licenses in Section 2.A(i)(a), (b), (c), or (d), AMYRIS shall, and shall cause each of its Affiliates
to, comply with all of its obligations under the Subject Third Party Agreements and will not terminate or amend such Subject Third
Party Agreement in each case in any manner which diminishes the licenses to TOTAL or increases any obligations of TOTAL with respect
to the AMYRIS Licensed IP that is subject to such Subject Third Party Agreement (“Detriment”) without
the consent of TOTAL and (b) with respect to Subject Third Party Agreements that are materially useful for TOTAL to practice the
licenses in Section 2.A(i)(a), (b), (c), or (d), AMYRIS shall provide advance written notice to TOTAL in connection with terminating
or amending such Subject Third Party Agreement that would result in a Detriment. In addition, AMYRIS will, and will cause each
of its Affiliates to, notify TOTAL promptly, if AMYRIS and/or any of its Affiliates receives notice, whether or not there is a
cure period, from a Third Party that AMYRIS and/or any of its Affiliates and/or other licensees is in material breach of any such
Subject Third Party Agreement if such material breach could result in a Detriment, and/or notice from any

    	 	31	 

    CONFIDENTIAL

    

 

Third Party which
purports to modify and/or terminate any such Subject Third Party Agreement in a manner that would cause a Detriment. AMYRIS will
and will cause its Affiliates to take prompt and commercially reasonable steps to cure any such breach. AMYRIS acknowledges that
any breach of such Subject Third Party Agreement(s) by AMYRIS and/or its Affiliates may result in damage to TOTAL with respect
to the subject AMYRIS Licensed IP, which may include loss of license rights to such AMYRIS Licensed IP and/or monetary damages.
For any Subject Third Party Agreement entered into by AMYRIS after the Effective Date that satisfies the criteria above, AMYRIS
agrees that it will use commercially reasonable efforts to obtain an agreement from the licensor that TOTAL can continue
with its sublicense if the license to AMYRIS under the applicable Subject Third Party Agreement is terminated, that TOTAL
may approach AMYRIS' licensors under the Subject Third Party Agreements for the limited purpose of obtaining an agreement from
such a licensor that TOTAL can continue with it sublicense if the license to AMYRIS under the applicable Subject Third Party Agreement
is terminated, and AMYRIS agrees that it shall facilitate such contact, on TOTAL's request, and AMYRIS will not object to
such an agreement.

 

(iii)             AMYRIS shall not enter into any agreement,
contract, lease, license, instrument or other arrangement with a Third Party that results in a breach of or constitutes a default
under this Agreement or that would conflict with the licenses and rights granted to TOTAL hereunder. 

 

(iv)            No member of the AMYRIS Family other than a Third
Party Acquirer shall commercialize, or grant any Third Party any rights to commercialize, any isoprenoid or isoprenoid-derived
compound for a Diesel Product in the Field in the Territory or otherwise conduct or authorize any activity in conflict with the
licenses granted in Section 2, provided that the exercise of its retained rights hereunder as set forth in Section 2.A(iii) above
shall not be construed as a violation of this clause (iv).

 

(v)           
Except as expressly contemplated in Section 2.A(i)(d), TOTAL shall not be obligated to pay to AMYRIS any fees of any type (including
royalties, milestones, maintenance, sublicense, etc.) beyond any amounts due under Section 2.A(v) or Section 2.B for its use,
license, sublicense and/or any other commercial exploitation of the licenses granted TOTAL herein with respect to the AMYRIS Licensed
IP.

 

(vi)            AMYRIS shall promptly inform TOTAL if AMYRIS and/or
any of its Affiliates becomes aware of any action, suit, investigation and/or proceeding pending and/or threatened before any arbitrator
and/or any governmental authority, in each case, to which AMYRIS or any of its Affiliates is a party, which could reasonably be
expected to have a material adverse effect on the ability of TOTAL and/or any of its Affiliates to practice any of the rights granted
TOTAL in this Agreement.

 

 (vii)            Until the expiration or termination of the Collaboration
Agreement, AMYRIS shall not, without prior notice to TOTAL, enter into any grant or contract that may provide any government or
non-for profit entity any rights (e.g., rights provided to the U.S. Government under 35 U.S. 200 et seq. or any similar provisions
of foreign law) to any patent

    	 	32	 

    CONFIDENTIAL

    

 

application or patents resulting from work done
in connection with such grant or contract that would be materially useful in connection with the conduct of the Biofene Development
Project or to Manufacture farnesene to make Licensed Products or to Make and Sell Licensed Products in the Field in the Territory.

 

(viii)            AMYRIS shall not, and shall not permit any Affiliate
to, create, incur, assume or permit to exist any Lien on any Invention within the AMYRIS Licensed IP owned by AMYRIS or its Affiliates
as of the Effective Date or hereafter acquired; provided, however, that AMYRIS and its Affiliates shall not be precluded by this
clause (viii) from granting licenses to its Affiliates and Third Parties under the AMYRIS Licensed IP, provided that such licenses
do not conflict with the licenses and other rights granted to TOTAL hereunder. For clarity, nothing in this clause (viii) shall
restrict the granting by AMYRIS of (a) licenses with respect to products other than Licensed Products, (b) licenses outside the
Field or (c) licenses within the scope of AMYRIS’ retained rights under Section 2.A(iii). 

 

  
(ix)            AMYRIS shall not, and shall not permit any Affiliate
to, use any Known By-Product to Make or Sell any Licensed Product in the Field in the Territory except in connection with the scope
of AMYRIS’ retained rights under Section 2.A(iii).

 

   (x)            AMYRIS shall not amend the terms of the IP License
Agreement with regard to its prohibition on Novvi’s sale of its by-products for use as diesel fuel in the Territory (the
“Novvi By-Product Restriction”), without the express prior written consent of TOTAL.

 

  
(xi)            In the event that TOTAL or AMYRIS become aware that
Novvi has breached the Novvi By-Product Restriction, it shall notify the other providing detailed information.
In the event that Novvi breaches the Novvi By-Product Restriction, AMYRIS, upon TOTAL’s written request, agrees to use its
best efforts to enforce the Novvi By-Product Restriction against Novvi including, if necessary, promptly commencing legal action
against Novvi to cease such breach and recover damages for such breach.

 

  (xii)            AMYRIS shall not, and shall not assist (by joining
as a party or otherwise) any Third Party to, commence or conduct any legal action against TOTAL or its sublicensees or Subcontractors
for the production of any By-Products in compliance with the terms of this Agreement.

 

E.                
Disclaimer. Except as provided in this ARTICLE 4, neither Party makes any
warranties to the other, whether express or implied, including without limitation any warranty of merchantability or fitness for
a particular purpose, as to any product or process, or as to the validity or scope of any of intellectual property or that the
practice of any of intellectual property will be free from infringement of any patent or other proprietary right of any Third Party
or TOTAL or any of its Affiliates.

    	 	33	 

    CONFIDENTIAL

    

 

Article
5.   INDEMNITY; LIMITATION OF LIABILITY

 

A.               
Indemnification.

 

(i)            Indemnification by TOTAL. TOTAL shall defend,
indemnify, and hold AMYRIS and AMYRIS’ officers, directors, employees, and agents (the “AMYRIS Indemnitees”)
harmless from and against any and all damages, liabilities, judgments, recoveries, costs, and expenses (including court costs and
reasonable attorneys’ fees and expenses), resulting from any claims, suits, actions or proceedings of any Third Party (collectively,
“Claims”) to the extent that such Claims arise out of, are based on, or result from (a) a breach of any of TOTAL’s
representations, warranties, covenants and/or obligations under this Agreement; (b) the willful misconduct or grossly negligent
acts of TOTAL or its Affiliates, or the officers, directors, employees, or agents of TOTAL or its Affiliates in connection with
its activities under this Agreement; or (c) the exercise by TOTAL of the licenses granted hereunder (excluding claims for infringement
and misappropriation of a Third Party’s intellectual property for which AMYRIS is obligated to indemnify TOTAL pursuant to
Section 5(A)(ii)(b) below); in each case except to the extent such Claims arise out of, are based on, or result from (x) a breach
by AMYRIS of any of AMYRIS’ representations, warranties, covenants and/or obligations under this Agreement; or (y) the willful
misconduct or grossly negligent acts of AMYRIS, its Affiliates, or the officers, directors, employees, or agents of AMYRIS or its
Affiliates.

 

(ii)            Indemnification by AMYRIS. AMYRIS shall defend,
indemnify, and hold TOTAL and its Affiliates and each of their officers, directors, employees, and agents (the “TOTAL
Indemnitees”) harmless from and against any and all damages, liabilities, judgments, recoveries, costs, and expenses
(including court costs and reasonable attorneys’ fees and expenses), resulting from any Claims (as defined in Section 5.A(i)
above) to the extent that (A) such Claims arise out of, are based on, or result from (a) a breach of any of AMYRIS’ representations,
warranties, covenants and/or obligations under this Agreement, (b) any manufacture by TOTAL of farnesene that allegedly has infringed
or misappropriated a Third Party’s intellectual property, but only to the extent such alleged infringement or misappropriation
is directly attributable to TOTAL’s adherence to AMYRIS’ then approved farnesene manufacturing process (as provided
in the Successful Commercial Transfer) licensed from AMYRIS as part of the AMYRIS Licensed IP and not to any deviation or modification
from such process made by or on behalf of TOTAL other than a deviation or modification made by TOTAL at the written direction of
AMYRIS, (c) the willful misconduct or grossly negligent acts of AMYRIS, its Affiliates, or the officers, directors, employees,
or agents of AMYRIS or its Affiliates or (B) such Claims (a) are Patent infringement claims brought by Novvi against TOTAL, (b) allege
that one or more of the Licensed Products infringes one or more Patents owned by Novvi and (c) are based on Inventions conceived
and reduced to practice by Novvi; in each case ((A) and (B)), except to the extent such Claims arise out of, are based on, or result
from (x) a breach by TOTAL of any of TOTAL’s representations, warranties, covenants and/or obligations under this Agreement;
or (y) the willful misconduct or grossly negligent acts of TOTAL and its Affiliates or the officers, directors, employees, or agents
of TOTAL or its Affiliates.

    	 	34	 

    CONFIDENTIAL

    

 

(iii)            Indemnification Procedures. In the event
that a Party claiming indemnity under this Section 5.A (the “Indemnified Party”) becomes aware of any Claim
for which it seeks indemnification from the other Party (the “Indemnifying Party”), the Indemnified Party shall:
(a) reasonably promptly notify Indemnifying Party thereof, in no event later than ten (10) business days after the Indemnified
Party becomes aware of such Claim (provided that failure to provide such notice will not release the Indemnifying Party from any
of its indemnity obligations hereunder except to the extent that such failure increases the Indemnifying Party's indemnity obligation);
(b) permit the Indemnifying Party to assume control of the defense or settlement of the Claim; (c) at the Indemnifying Party’s
expense, provide the Indemnifying Party with reasonable cooperation in the defense or settlement thereof; and (d) not settle any
such claim without the Indemnifying Party’s written consent, not to be unreasonably withheld. The Indemnified Party may participate
in and monitor such defense with counsel of its own choosing at its sole expense. If the Indemnifying Party does not assume and
conduct the defense of the claim as provided above, (x) the Indemnified Party may defend against, and consent to the entry of any
judgment or enter into any settlement with respect to the claim in any manner the Indemnified Party may deem reasonably appropriate
(and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith),
and (y) the Indemnifying Party shall remain responsible to indemnify the Indemnified Party as provided in this Section 5.A.

 

B.                
Insurance. Prior to the commencement of its operational activities, TOTAL shall acquire, and thereafter maintain,
product liability insurance and general commercial liability insurance, to the extent, in amounts and from carriers with quality
ratings not lower than industry standards for a similarly situated company, during the Term and thereafter for so long as TOTAL
is exercising its license rights granted hereunder and including with respect to TOTAL’s facilities used in conducting such
activities. TOTAL shall provide to AMYRIS a certificate of insurance evidencing such coverage upon request.

 

C.                
Limitation of Liability. EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS
AFFILIATES OR WITH RESPECT TO A BREACH OF ARTICLE 6, NEITHER PARTY, NOR ANY OF ITS AFFILIATES, SHALL BE ENTITLED TO RECOVER FROM
THE OTHER PARTY ANY SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER.
FOR CLARITY, ANY DAMAGES FINALLY AND ACTUALLY SUFFERED BY AN INDEMNIFIED PARTY (WHETHER BY A FINAL JUDGMENT OF A COURT OF LAW OR
THROUGH A SETTLEMENT) ARISING OUT OF A CLAIM FOR WHICH THE INDEMNIFIED PARTY IS INDEMNIFIABLE UNDER THIS ARTICLE 5 SHALL BE DEEMED
DIRECT DAMAGES FOR PURPOSE OF THIS SECTION 5.C. NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE ENTITLED TO RECOVER FROM THE OTHER
PARTY ANY PUNITIVE DAMAGES HEREUNDER.

    	 	35	 

    CONFIDENTIAL

    

 

Article
6.   CONFIDENTIALITY

 

A.               
Confidential Information. Except to the extent expressly authorized by this Agreement or otherwise provided herein
or agreed in writing by the Parties, during the Term and for two (2) years thereafter, each Party shall keep confidential and shall
not publish or otherwise disclose and shall not use for any purpose other than as permitted in this Agreement or the Collaboration
Agreement, any Inventions or other confidential information, including any information relating to any Strain, disclosed to it
by the other Party or its Affiliates pursuant to this Agreement (collectively, “Confidential Information” of
the disclosing Party). Each Party shall use at least the same standard of care as it uses to protect proprietary or confidential
information of its own, but in no event less than reasonable care, to ensure that its and its Affiliates’ and sublicensees’
employees, previous employees, agents, consultants and other representatives do not disclose or make any unauthorized use of the
Confidential Information of the other Party. Each Party shall promptly notify the other upon discovery of any unauthorized use
or disclosure of the other Party’s Confidential Information. The terms and conditions of this Agreement (but not the existence
hereof) shall be the Confidential Information of both Parties. Any Confidential Information disclosed hereunder shall be the Confidential
Information of the disclosing Party. The receiving Party is permitted to use such Confidential Information only to the extent permitted
in this Agreement or the Collaboration Agreement. Any Inventions owned by AMYRIS under this Agreement (including by reference to
the Collaboration Agreement in Section 3.A(i) above) shall constitute Confidential Information of AMYRIS.

 

B.                
Exceptions. The obligations of non-disclosure and non-use under Section 6.A shall not apply to any Confidential Information
of a disclosing Party if the receiving Party can prove by contemporaneous written documentation or otherwise reasonably demonstrate
that such Confidential Information: (1) is at the time of receipt, or thereafter becomes, through no breach of this Agreement or
the Collaboration Agreement by the receiving Party, generally known or publicly available; (2) is known by the receiving Party
at the time of receiving such Confidential Information; (3) is hereafter furnished to the receiving Party by a Third Party, which
is not, to the receiving Party’s reasonable knowledge, in breach of any confidentiality obligation related to such information;
(4) is independently discovered or developed (in the case of TOTAL, without the practice of the licenses granted hereunder or reference
to the AMYRIS Licensed IP or the Confidential Information of AMYRIS, and without use of Confidential Information of AMYRIS under
the Collaboration Agreement and without violation of any agreement between AMYRIS and any of its Affiliates, on the one hand, and
TOTAL or any of its Affiliates, on the other hand), (5) is the subject of a written permission to disclose provided by the disclosing
Party; or (6) is disclosed pursuant to any ruling of a governmental or regulatory authority or court or by mandatory law, provided
that written notice of such ruling is given, as soon as reasonably possible, to the disclosing Party so as to give the disclosing
Party an opportunity to intervene and provided further that the receiving Party uses reasonable efforts to obtain assurance that
the Confidential Information shall be treated confidentially. In addition, each Party may disclose Confidential Information of
the other Party to the extent such disclosure is reasonably necessary in the following instances:

    	 	36	 

    CONFIDENTIAL

    

 

(i)            filing or prosecuting Patents as permitted by this
Agreement (but such disclosure must comply with Section 6(C) below);

 

(ii)            regulatory filings for products to which such Party
has a license or a right to develop hereunder;

 

(iii)           
prosecuting or defending litigation as permitted by or relating to this Agreement;

 

(iv)            otherwise required by law or the requirements of
a national securities exchange or other similar regulatory body; provided that the receiving Party shall (a) provide the disclosing
Party with reasonable advance notice of, and an opportunity to comment on, any such required disclosure, to the extent such advance
notice is legally permitted, (b) if requested by the disclosing Party, and at the disclosing Party’s expense, seek confidential
treatment with respect to any such disclosure to the extent available, and (c) use good faith efforts to incorporate the comments
of the disclosing Party in any such disclosure or request for confidential treatment;

 

(v)            complying with applicable Legal Requirements or governmental
requests;

 

(vi)            disclosure to its Affiliates, licensees, sublicensees
and Subcontractors and their respective representatives, who reasonably need to know such Confidential Information for the purpose
of performing the obligations or exercising its license rights as described in this Agreement and internal reporting to its Affiliates,
provided, in each case, each Party shall be responsible for ensuring that all such representatives to whom the Confidential Information
is disclosed under this Agreement shall keep such information confidential and shall not disclose the same to any unauthorized
person; or

 

 (vii)            to underwriters or investors or potential investors
or their counsel or accountants in connection with a Monetization (as defined in Section 13.6 of the Collaboration Agreement) or
other investment transaction (and to its and their respective Affiliates, representatives and financing sources); provided, however,
that each such Third Party to whom information is disclosed will (a) be subject to obligations of confidentiality substantially
similar hereunder, (b) be informed of the confidential nature of the Confidential Information so disclosed, and (c) agree to hold
such Confidential Information subject to the terms thereof; provided, that the disclosure rights shall not apply with respect to
the other Party’s intellectual property.

 

C.                
Public Disclosures of Technical Information. If TOTAL seeks to publish any technical information relating to any
Strain, the substance of which has not been previously approved by AMYRIS for publication or disclosure, TOTAL shall first provide
to AMYRIS the material proposed for disclosure or publication, such as by oral presentation, manuscript or abstract, and AMYRIS
shall have the right to review and comment on all such material. Before any such material is submitted for publication,

    	 	37	 

    CONFIDENTIAL

    

 

TOTAL shall deliver a complete copy to AMYRIS
at least sixty (60) days prior to submitting the material to a publisher or initiating any other disclosure. AMYRIS shall review
any such material and give its comments to TOTAL as soon as practicable, but no later than forty-five (45) days after delivery
of such material to TOTAL. TOTAL shall not publish any such technical information, the substance of which has not been previously
approved by AMYRIS for publication or disclosure, without AMYRIS’ prior written consent in each instance, which consent shall
not be unreasonably withheld or delayed. For clarity, such consent is not required for disclosures relating to the Licensed Products
to the extent such disclosure does not comprise technical information relating to Strains.

 

D.               
Publicity and Disclosure of this Agreement. A Party that desires to make, or that is required to make pursuant to
applicable laws or regulations, any press release or other public disclosure regarding the existence or terms of this Agreement
(including the identity of the other Party to this Agreement) shall first consult with the other Party (to the extent such consultation
does not violate applicable laws or regulations) with respect to the text and timing of such press release or other public disclosure
and shall obtain the other Party’s approval over the text and timing of such release and disclosure prior to the issuance
or disclosure thereof (to the extent such approval does not violate applicable laws or regulations). Following the initial press
release or other public disclosure announcing the existence or terms of this Agreement (if any), each Party shall be free to disclose,
without the other Party’s prior written consent, the existence of this Agreement, the identity of the other Party and those
terms of this Agreement which have already been publicly disclosed in accordance herewith.

 

E.                
Residuals. Nothing in this Agreement shall restrict any employee or representative of a Party from using general
ideas, concepts, practices, learning, or know-how relating to any activities conducted on behalf of TOTAL (“General Know-How”)
that are retained in the unaided memory of such employee or representative following performance of the Biofene Development Project
and such employee or representative is not aware at the time of use that such information is Confidential Information of
the other Party, provided that the foregoing is not intended to grant, and shall not be deemed to grant (i) any right to disclose
the Confidential Information of the other Party, or (ii) any license under any Patents of the other Party. The General Know-How
shall in no event include any financial, business statistical, or personnel information specific to the other Party. A person’s
memory is “unaided” if such person has not intentionally memorized the Confidential Information for the purpose of
retaining and subsequently using or disclosing it otherwise than as authorized pursuant to this Agreement.

 

Article
7.   TERM AND TERMINATION

 

A.               
Term. The term of this Agreement shall commence on the Effective Date and remain in effect for fifty (50) years (the
“Term”).

    	 	38	 

    CONFIDENTIAL

    

 

B.                
Consequence of Events. The Parties agree as follows:

 

(i)            Change of Control of AMYRIS. For clarity, this
Agreement shall remain in full force and effect in the event of any Change of Control of AMYRIS.

 

(ii)            Termination of Collaboration Agreement. For
clarity, the Parties agree that, regardless of any termination of the Collaboration Agreement, this Agreement shall remain in full
force and effect according to its terms.

 

C.                
Termination of Agreement.

 

(i)            The licenses granted to TOTAL herein shall be irrevocable
(other than as specified in this Section 7.C), provided in the case of a material breach (but only in the case of a material breach)
of the relevant license, AMYRIS shall have a right to terminate the applicable license in accordance with the following. If AMYRIS
believes any such breach by TOTAL has occurred, AMYRIS shall within thirty (30) days provide written notice to TOTAL describing
the specific alleged material breach. If a material breach is not cured within ninety (90) days of TOTAL’s receipt of such
notice, then AMYRIS may terminate the applicable license with further written notice to TOTAL (A) immediately at the end of such
ninety (90) day period, if TOTAL has not contested the allegation, or (B) if TOTAL has contested such allegation, only upon a final
written determination, if any, of an arbitrator in a proceeding subject to Section 8.B that an uncured material breach has occurred.
For clarity, in the case of any dispute between the Parties as to whether any uncured material breach has occurred that would permit
AMYRIS to terminate a license or this Agreement, no notice of termination may be given and no such termination shall be effective
until the final resolution of a dispute resolution proceeding conducted pursuant to Section 8.B, and such licenses may only be
terminated if the arbitrator finally determines an uncured material breach has occurred.

 

(ii)            In the case of an uncured material breach of Section 2.E(i)
or (ii) by TOTAL, then, except to the extent Section 7.C(iii) below applies, AMYRIS shall have the right to terminate the
licenses granted in Section 2.A in their entirety in accordance with the procedure described in Section 7.C(i) above, and in the
case of such a license termination, this Agreement shall terminate concurrently.

 

(iii)           
In the case of any uncured material breach by TOTAL based on the use of any Intermediate Strain or any other Strain that is a
genetic manipulation or modification of any Intermediate Strain (other than any Commercial Farnesene Strain(s)) outside the scope
of the limited license in Section 2.A(i)(b), then in accordance with the procedure described in clause 7.C(i) above, AMYRIS shall
have the right to terminate the license granted in Section 2.A(i)(b) and all other rights of TOTAL permitting its development
and use of Intermediate Strains, including TOTAL’s right to release of the Escrowed Materials relating to the Intermediate
Strains) as described in clause (i) above but AMYRIS may not otherwise terminate any provision of this Agreement or this Agreement
in its entirety.

    	 	39	 

    CONFIDENTIAL

    

 

(iv)           
For purposes of determining whether a material breach that would trigger a right of termination under Section 7.C has occurred,
any Affiliate of TOTAL shall be treated as if it was TOTAL.

 

(v)            Except as expressly provided in this Section 7.C(v),
no acts or omissions of any Subcontractor or sublicensee of TOTAL shall be the basis of any termination of this Agreement. In the
event that any Subcontractor or sublicensee of TOTAL violates Section 2.E(i) or Section 2.E(ii)(a) or (b), then such violation
may provide a basis for a material breach and termination of this Agreement under Section 7.C(ii) above, but only if TOTAL fails
to use commercially reasonable efforts to cure such breach, which efforts may include terminating its agreement with such Subcontractor
or sublicensee and initiating and continuing to pursue appropriate legal action to stop such unauthorized activity. In the event
that a sublicensee or Subcontractor of TOTAL uses any Intermediate Strain in a manner that exceeds the scope of or violates the
restrictions on the exercise of the license in Section 2.A(i)(b), then in accordance with the procedure described in Section
7.C(i) above, AMYRIS shall have the right to terminate the license in Section 2.A(i)(b) pursuant to Section 7.C(iii) and TOTAL’s
related rights in respect of Intermediate Strains but only if TOTAL is not using commercially reasonable efforts to cure such breach,
which efforts may include terminating its agreement with Affiliate, sublicensee or Subcontractor pertaining to the Intermediate
Strain(s) and initiating and continuing to pursue appropriate legal action to stop such unauthorized activity.  

 

D.               
Conversion to Non-Exclusive License. In the event of the expiration of this Agreement at the end of the Term, TOTAL
shall retain a perpetual, non-exclusive, royalty-free (subject to Section 2.A(v) and Section 2.B) right and license under
the AMYRIS Licensed IP, in each case that is necessary or, in the case of the AMYRIS Farnesene Production IP, useful to
Make and Sell Licensed Products within the Field within the Territory.

 

E.                
Effects of Termination.

 

1.                 
Strains; Return or Destruction of Confidential Information. Except as provided in Section 7.D, upon expiration
or termination of this Agreement and/or the licenses granted herein, as applicable, TOTAL shall immediately cease and cause its
Affiliates, sublicensees and Subcontractors to cease use of any AMYRIS Licensed IP, Strain Improvement Technology and all TOTAL
Strains (or in the case of a termination under Section 7.C(iii), the Intermediate Strains and any Strains derived therefrom) and
within ninety (90) days following a written request from the other Party, each receiving Party shall at the disclosing Party’s
discretion, promptly destroy or return to the disclosing Party (a) all written copies of the disclosing Party’s Confidential
Information that is marked confidential and (b) all biological materials (including all TOTAL Strains), in each case (a) and (b)
to which the receiving Party does not retain rights hereunder, except that the receiving Party may retain such Confidential Information
or materials, to the extent that the receiving Party requires such Confidential Information or materials for the purpose of performing
any obligations under this Agreement that may survive such expiration or termination, or with respect to Confidential Information
only for archival purposes or for

    	 	40	 

    CONFIDENTIAL

    

 

information contained in management reports.

 

2.                 
Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement to TOTAL are, and will
otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code (the “Bankruptcy Code”),
licenses of rights to “intellectual property” as that term is defined in the Bankruptcy Code. TOTAL, as a licensee
of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code.
Upon the filing of a case by or against AMYRIS or any AMYRIS Affiliate (the “Bankrupt Entity”), including without
limitation, AMYRIS Fuels LLC, AB Technologies LLC, and/or AMYRIS Brasil Ltda. (each of such Affiliates, a “Co-Licensor”)
under the Bankruptcy Code, then (a) TOTAL shall be entitled to the fullest protections conferred upon licensees under Section 365(n)
of the Bankruptcy Code, or any similar provision; (b) AMYRIS and each Co-Licensor shall perform all of its obligations under this
Agreement; (c) the Bankrupt Entity shall immediately, without the need for any further request by TOTAL, or notice or hearing,
provide to TOTAL a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments
of such intellectual property (which embodiments, throughout this Agreement, shall include without limitation, the Escrowed Materials),
or any other information necessary or desirable for TOTAL to utilize such intellectual property; and (d) AMYRIS and each Co-Licensor
shall not interfere with the rights of TOTAL as provided in this Agreement, or in any agreement supplementary to this Agreement,
to such intellectual property (including such embodiment), including any right to obtain such intellectual property (and such embodiment)
from another entity or person. To the extent AMYRIS and/or a Co-Licensor rejects this Agreement under the Bankruptcy Code and TOTAL
elects to retain its rights, (x) TOTAL shall have the full rights provided to it under Section 365(n) of the Bankruptcy Code; (y)
the waivers under Section 365(n)(2)(C) shall apply only to rights of setoff and administrative claims arising solely out of this
Agreement, and not to any other agreements or instruments, including, without limitation, claims or rights arising out of agreements
supplementary to this Agreement; and (z) the Bankrupt Entity shall, without need for notice or hearing, provide to TOTAL any intellectual
property (including such embodiment) held by AMYRIS and/or each Co-licensor and/or any other entity or person, and shall not interfere
with the rights of TOTAL as provided in this Agreement, or any agreement supplementary to this Agreement, to such intellectual
property (including such embodiment) including any right to obtain such intellectual property (and such embodiment) from another
entity or person. For purposes of this Agreement, the term “embodiment” shall mean any and all materials required to
be delivered by AMYRIS or a Co-Licensor to TOTAL hereunder and any materials relating to the licenses granted hereunder which,
in the course of dealing between the Parties under this Agreement, are customarily delivered, in whatever format (whether electronic,
written or otherwise). All written agreements entered into relating to and in connection with the Parties’ performance hereunder
from time-to-time, shall be considered agreements “supplementary” to this Agreement for purposes of Section 365(n)
of the Bankruptcy Code. AMYRIS and each Co-Licensor acknowledges and agrees that the rights of TOTAL to such intellectual property
(and such embodiments) are unique, and that to the extent AMYRIS or a Co-Licensor, or their respective trustees in bankruptcy,
were to sell any portion of such

    	 	41	 

    CONFIDENTIAL

    

 

intellectual property
free and clear of liens, claims or interests, TOTAL would suffer irreparable damages, such that AMYRIS and each Co-Licensor
agrees that such sale shall not occur without TOTAL’s express written consent. For the avoidance of doubt, “intellectual
property,” as used in this Section 7.E.2, is limited to intellectual property included in the AMYRIS Licensed IP and the
Strain Improvement Technology, and any tangible embodiments of such intellectual property, and includes all such intellectual property
and tangible embodiments of such intellectual property (provided in the case of the Strain Improvement Technology, only to the
extent, and for the uses and period, described in Section 2.A.(i)(b)).  

 

3.                 
Accrued Rights. Termination or expiration of this Agreement for any reason shall not release either Party from any
liability or obligation that already has accrued prior to such expiration or termination, nor affect the survival of any provision
hereof to the extent it is expressly stated to survive such termination. Termination or expiration of this Agreement for any reason
shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies or claims,
whether for damages or otherwise, that a Party may have hereunder or that may arise out of or in connection with such termination
or expiration.

 

F.                 
Survival. Subject to the other provisions set forth in this Article 7 and any other applicable terms and conditions
of this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration
of this Agreement: Articles 1 (Definitions) (to the extent any definitions are applicable after expiration hereof), 5 (Indemnity;
Limitation of Liability), 6 (Confidentiality) (for the period set forth therein), 8 (Dispute Resolution) and 9 (Miscellaneous);
Sections 2.A (License to Make and Sell Licensed Products) (where the licenses are on the non-exclusive basis described above),
2.B (Third Party Agreements), 2.C (Sublicenses and Subcontracts), 2.E (Strain Restrictions), 2.F (Reporting, Audit and Inspection
Rights), 2.G (No Implied Rights), 2.I, 3.A (Ownership), 3.E (Infringement of Third Party Rights), 3.F (Common Interest Disclosures
and Agreement), 4.E (Disclaimer), 7.C (Termination of Agreement), 7.D (Conversion to Non-Exclusive License) and 7.E (Effects of
Termination); and this Section 7.F (Survival). Subject to the other provisions set forth in this Article 7 and any other applicable
terms and conditions of this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement
shall survive termination of this Agreement: Articles 1 (Definitions) (to the extent any definitions are applicable after termination
hereof), 5 (Indemnity; Limitation of Liability), 6 (Confidentiality) (for the period set forth therein), 8 (Dispute Resolution)
and 9 (Miscellaneous); Sections 3.A (Ownership), 3.E (Infringement of Third Party Rights), 3.F (Common Interest Disclosures and
Agreement), 4.E (Disclaimer), 7.C (Termination of Agreement) and 7.E (Effects of Termination); and this Section 7.F (Survival).

 

Article
8.   DISPUTE RESOLUTION

 

A.               
Escalation. Except as provided in Section 8.B or 8.D, if any Dispute arises between the Parties under this Agreement,
such Dispute shall be referred to the Executive Officers for further discussion and resolution. The Executive Officers shall attempt
in good

    	 	42	 

    CONFIDENTIAL

    

 

faith to resolve any Dispute referred to them
pursuant to this Section 8.A within ten (10) days after such referral by meeting (either in person or by video teleconference,
unless otherwise mutually agreed) at a mutually acceptable time, and thereafter as often as they reasonably deem necessary, to
exchange relevant information and to attempt to resolve the Dispute. If the Dispute has not been resolved within twenty (20) days
thereafter and the Dispute does not consist of a failure by the Parties to reach agreement where one or both Parties have discretion
whether to agree, either Party may, by written notice to the other Party, elect to initiate arbitration pursuant to Section 8.B
for purposes of having the Dispute and any related Disputes resolved. If an Executive Officer intends to be accompanied at a meeting
by an attorney, the other Executive Officer shall be given at least forty-eight (48) hours’ notice of such intention and
may also be accompanied by an attorney. All negotiations conducted pursuant to Section 8.B, and all documents and information exchanged
by the Parties in furtherance of such negotiations, (i) are the Confidential Information of the Parties, (ii) shall be treated
as evidence of compromise and settlement for purposes of the United States Federal Rules of Evidence and any other applicable state
or national rules of evidence or procedure, and (iii) shall be inadmissible in any arbitration conducted pursuant to this Section
8 or other proceeding with respect to a Dispute.

 

B.                
Arbitration. Except for Disputes that are subject to Sections 8.C, D or E, all Disputes arising out of or in connection
with this Agreement that cannot be resolved by the Executive Officers pursuant to Section 8.A shall be finally settled as follows:

 

(i)            Except for Disputes that are subject to Section 8.C,
D or E, all Disputes arising out of or in connection with this Agreement that cannot be resolved by the Executive Officers pursuant
to Section 8.A, shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce (the “ICC
Rules”) by an arbitration tribunal appointed in accordance with the said ICC Rules as modified hereby.

 

                                                  
(ii)            There shall be three (3) arbitrators, one selected
by the initiating Party in the request for arbitration, the second selected by the other Party within twenty (20) days of receipt
of the request for arbitration, and the third (who shall act as chairperson of the arbitration tribunal) selected by the two (2)
Party-appointed arbitrators within twenty (20) days of the selection of the second arbitrator. In the event that the respondent
fails to select an arbitrator, or if the two Party-appointed arbitrators are unable or fail to agree upon the third arbitrator,
the international Court of Arbitration of the International Chamber of Commerce shall designate the remaining arbitrator(s) required
to comprise the tribunal. The claimant in the arbitration shall provide a copy of the request for arbitration to the respondent
at the time such request is submitted to the Secretariat of the International Chamber of Commerce.

 

(iii)            Each arbitrator chosen under this Section shall
speak, read, and write English fluently and shall be either (a) a practicing lawyer who has specialized in business litigation
with at least ten (10) years of experience in a law firm of over fifty (50) lawyers or (b) a retired judge of a court of general
jurisdiction.

    	 	43	 

    CONFIDENTIAL

    

 

(iv)            The place of arbitration shall be New York, New York.
The language of the arbitral proceedings and of all submissions and written evidence shall be English; provided, however, that
a Party, at its expense, may provide for translation or simultaneous interpretation into a language other than English.

 

(v)            The arbitrators shall issue an award within nine (9)
months of the submission of the request for arbitration. This time limit may be extended by agreement of the Parties or by the
tribunal if necessary.

 

(vi)            It is expressly understood and agreed by the Parties
that the rulings and award of the tribunal shall be conclusive on the Parties, their successors and permitted assigns. Judgment
on the award rendered by the tribunal may be entered in any court having jurisdiction thereof.

 

(vii)            Each Party shall bear its own costs and expenses
and attorneys' fees, and the Party that does not prevail in the arbitration proceeding shall pay the arbitrator's fees and any
administrative fees of arbitration. All proceedings and decisions of the tribunal shall be deemed Confidential Information of each
of the Parties, and shall be subject to Article 6.

 

For clarity, any disputes between the Parties
regarding the deposit of Escrowed Materials or access to any Escrowed Materials shall not be required to be resolved via arbitration,
and either Party may seek equitable relief for such dispute, including without limitation, specific performance, pursuant to Section 8.D.

 

C.                
Patent Validity and Infringement Disputes. In the event that a Dispute arises with respect to the inventorship, scope,
validity, enforceability, revocation or infringement of a Patent, and such Dispute cannot be resolved by the Executive Officers
in accordance with Section 8.A, unless otherwise agreed by the Parties in writing, such Dispute shall not be submitted to arbitration
in accordance with Section 8.B, and notwithstanding anything in this Agreement to the contrary, the sole forum to resolve such
Dispute shall be to initiate litigation in a court or other tribunal of competent jurisdiction in the country of issuance of the
Patent that is the subject of the Dispute.

 

D.               
Equitable Relief. Notwithstanding anything to the contrary, either Party may at any time seek to obtain equitable
relief from a court of competent jurisdiction with respect to an issue arising under this Agreement if the rights of such Party
would be prejudiced absent such relief.

 

E.                
Disputes Subject to Section 2.A(iii). In the event of any disagreement between the Parties (or their successors)
regarding the terms on which any Inventions subject to Section 2.A(iii) shall be licensed to Company, then at the request of Company
(or its successor), such dispute be resolved by a single arbitrator agreed by the Parties or if the Parties are unable to agree
within thirty (30) days of Company’s request, selected by the head of the New York office of the International Chamber of
Commerce. Such arbitrator shall have expertise in the licensing of biotechnology intellectual property for industrial

 

    	 	44	 

    CONFIDENTIAL

    

applications. Each Party shall submit to the arbitrator
a written brief of its position regarding the license terms, which submission (including supporting documentation) shall not exceed
50 pages. The arbitrator shall select the position of one of the Parties, in its entirety, as his or her decision, and shall have
no authority to vary any of the terms of the prevailing proposal. The Parties shall equally share the costs of such arbitration.
Any such arbitration shall be completed within 120 days of selection of the arbitrator.

 

F.                 
Attorney’s Fees. If any action, proceeding or arbitration is brought by a Party to enforce or interpret this
Agreement, the prevailing Party, in addition to all other legal or equitable remedies possessed, shall be entitled to be reimbursed
for all reasonable attorneys’ fees incurred by reason of such action or proceeding to the extent related to the enforcement
or interpretation of this Agreement.

 

Article
9.   MISCELLANEOUS

 

A.               
Governing Law. This Agreement and any arbitration hereunder shall be governed by, interpreted and construed and enforced
in accordance with, the laws of the State of New York, without giving effect to any conflicts of laws principles thereof.

 

B.                
Entire Agreement; Modification. This Agreement and the Collaboration Agreement constitute the entire agreement of
the Parties with respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral,
among the Parties with respect to the subject matter hereof. No warranty, representation, inducement, promise, understanding
or condition not set forth in this Agreement has been made or relied upon by either Party with respect to the subject matter of
this Agreement. No rights or licenses with respect to any intellectual property right of either Party are granted or deemed granted
hereunder or in connection herewith, other than those rights expressly granted in this Agreement. This Agreement may only be modified
or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement. For clarity, except
as modified herein, the Collaboration Agreement remains in full force and effect; provided, in the event of any inconsistency between
the Collaboration Agreement and this Agreement, the terms of this Agreement shall prevail.

 

C.                
Relationship. This Agreement establishes between the Parties an independent relationship. The Parties intend that
no partnership or joint venture is created hereby between TOTAL and AMYRIS, that neither Party will be a partner or joint venturer
of the other Party for any purposes, and that this Agreement will not be construed to the contrary.

 

D.               
Non-Waiver. Either Party may (i) extend the time for the performance of any of the obligations or other acts of the
other Party, (ii) waive any inaccuracies in the representations and warranties of the other Party contained herein or in any document
delivered by the other Party pursuant hereto, or (iii) waive compliance with any of the agreements or conditions of the other Party
contained herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by the Parties.
Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach

 

    	 	45	 

    CONFIDENTIAL

    

or a subsequent waiver of the same term or condition,
or a waiver of any other term or condition, of this Agreement. The failure of either Party to assert any of its rights hereunder
shall not constitute a waiver of any of such rights. Any extension of time or other indulgence granted to a Party hereunder shall
not otherwise alter or affect any power, remedy or right of the other Party or the obligations of the Party to whom such extension
or indulgence is granted.

 

E.                
Assignment. This Agreement may not be assigned by either Party without the express written consent of the other Party;
provided, however, that either Party may assign its rights and obligations pursuant to this Agreement without the written consent
of the other Party to (a) any of its Affiliates or (b) in connection with the transfer or sale by a Party of all or substantially
all the assets to which this Agreement relates; provided, that any such assignee agrees to be bound by the terms of this
Agreement.

 

F.                 
Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced
by any applicable law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force
and effect to the fullest extent permitted by law. Upon determination that any term or other provision is invalid, illegal or incapable
of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the
Parties as closely as possible in a reasonably acceptable manner.

 

G.               
Notices. Any notice to be given under this Agreement must be in writing and delivered either in person by registered
or certified mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any
of the foregoing, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated
by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of (a) the date
of actual receipt; (b) if mailed, three (3) days after the date of postmark; or (c) if delivered by overnight courier, the next
business day the overnight courier regularly makes deliveries.

 

If to TOTAL, notices must be addressed
to:

 

Total Energies Nouvelles Activités
USA

 24 Cours Michelet

 92800 Puteaux

 France

Attn:                           , President

 Fax. No.:

 Email:

    	 	46	 

    CONFIDENTIAL

    

 

If to AMYRIS, notices must be addressed
to:

 

AMYRIS, Inc.

 5885 Hollis Street, Suite
100

 Emeryville, CA 94608

 Attention: General Counsel

 Facsimile:

 

H.               
Force Majeure. Each Party shall be excused from liability for the failure or delay in performance of any obligation
under this Agreement by reason of any event beyond such Party’s reasonable control including but not limited to acts of God,
fire, flood, explosion, earthquake, or other natural forces, war, civil unrest, accident, any strike or labor disturbance, or any
other event similar to those enumerated above. Such excuse from liability shall be effective only to the extent and duration of
the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur and
continues to use diligent, good faith efforts to avoid the effects of such event and to perform the obligation. Notice of a Party’s
failure or delay in performance due to force majeure must be given to the unaffected Party promptly thereafter but no later than
five (5) days after its occurrence which notice shall describe the force majeure event and the actions taken to minimize the impact
thereof. All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such
force majeure. In no event shall any Party be required to prevent or settle any labor disturbance or dispute.

 

I.                  
Trademarks and Logos. Neither Party shall use, in advertising or otherwise, the other Party’s or its Affiliates’
names, trade names, trademarks, service marks, logos or other indicia of origin or refer to the other Party or its Affiliates,
directly or indirectly, in any media release, public announcement or public disclosure relating to this Agreement or its subject
matter, including in any promotional or marketing materials, lists, referral lists, or business presentations, without prior written
consent from the other Party for each such use or release. The restrictions imposed by this Section 9.I shall not prohibit either
Party from making any disclosure (a) identifying the other Party as a counterparty to this Agreement to its or its Affiliates’
actual or prospective acquirers, merger candidates, underwriters, or investors (and their attorneys and accountants), (b) that
is required by Applicable Law or the requirements of a national securities exchange or another similar regulatory body (provided
that any such disclosure shall be governed by Section 6) or (c) with respect to which written consent of the other Party has
previously been obtained.

 

J.                  
Export Control. Notwithstanding anything to the contrary contained herein, all obligations of the Parties are subject
to prior compliance with export regulations applicable to each Party and such other related laws and regulations as may be applicable
to each Party, and to obtaining all necessary approvals required by the applicable government entity. Each Party shall each use
its reasonable efforts to obtain such approvals for its own activities. Each Party shall cooperate with the other Parties and shall
provide assistance to the other Parties as reasonably necessary to obtain any required approvals.

 

K.               
Interpretation.

    	 	47	 

    CONFIDENTIAL

    

 

(i)            Captions & Headings. The captions and headings
of clauses contained in this Agreement preceding the text of the articles, sections, subsections and paragraphs hereof are inserted
solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its
interpretation or construction.

 

(ii)           
Singular & Plural. All references in this Agreement to the singular shall include the plural where applicable, and
all references to gender shall include both genders and the neuter.

 

(iii)            Including as Example. Use of the term “including”
or “include” in this Agreement shall be interpreted to mean “including, without limitation,” or “include,
but not limited to,” and shall be exemplary rather than restrictive.

 

(iv)            Sections & Subsections. Unless otherwise
specified, references in this Agreement to any section shall include all subsections and paragraphs in such sections, and references
in this Agreement to any subsection shall include all paragraphs in such subsection.

 

(v)            Days. All references to days in this Agreement
mean calendar days, unless otherwise specified.

 

(vi)            Ambiguities. Ambiguities and uncertainties
in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused
the ambiguity or uncertainty to exist.

 

(vii)            English Language. All notices required or
permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding this Agreement
shall be in the English language.

 

L.                
Drafting. Each Party agrees that it participated equally with the other in the drafting of this Agreement, using
counsel of its choice. This Agreement shall be interpreted without regard to any principle of construction regarding the drafting,
authorship or revision thereof.

 

M.              
Further Assurances. After the Effective Date, each of the Parties shall execute and deliver such additional documents,
certificates, and instruments and perform such additional acts, as may be reasonably requested and necessary or appropriate to
carry out the purposes and intent and all of the provisions of this Agreement and to consummate all of the transactions contemplated
by this Agreement.

 

N.               
License Registrations. TOTAL may, at its expense, register the exclusive licenses granted under this Agreement in
any country of, or community or association of countries in, the Territory. AMYRIS shall reasonably cooperate in such registration
at TOTAL’s expense. Upon request by TOTAL, AMYRIS agrees promptly to execute any "short form" licenses developed
in a form reasonably acceptable to both TOTAL and AMYRIS and reasonably submitted to it by TOTAL from time to time in order to
effect the

 

    	 	48	 

    CONFIDENTIAL

    

foregoing registration in such country. No such
"short form" license shall be deemed to amend or be used to interpret this Agreement. If there is any conflict between
such a license or other recordation document and this Agreement, this Agreement shall control.

 

O.               
Counterparts. This Agreement and any amendments hereto may be executed in one or more counterparts, all of which
shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each
Party and delivered to the other Party, it being understood that both Parties need not sign the same counterpart. Any such counterpart,
to the extent delivered by electronic delivery, shall be treated in all manner and respects as an original executed counterpart
and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.
Neither Party shall raise the use of electronic delivery to deliver a signature, or the fact that any signature or agreement or
instrument was transmitted or communicated through the use of electronic delivery, as a defense to the formation of a contract,
and each Party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

 

P.                 
Affiliates. Each Party hereto shall be responsible for ensuring that its Affiliates (whether existing as of the Effective
Date or thereafter during the Term of this Agreement) comply with the terms of this Agreement.

 

[Signatures on following page]

 

 

 

 

 

 

 

 

    	 	49	 

    CONFIDENTIAL

    

 

THIS AGREEMENT IS EXECUTED by the authorized representatives of the
Parties as of the date first written above.

 

	AMYRIS, Inc.	 	TOTAL ENERGIES NOUVELLES ACTIVITÉS USA 
	 	 	 	 	 	 
	By: 	/s/ Nicholas Khadder	 	By: 	 	 
	Name:	Nicholas Khadder	 	Name:	 	 
	Title:	General Counsel & Corp Secretary	 	Title:	 	 

 

 

The following AMYRIS Affiliates existing as of the Effective Date of
this Agreement hereby acknowledge and approve the licenses granted to TOTAL in Section 2.A and Section 7.E.2 of this
Agreement.

 

	AMYRIS Fuels LLC	 	 	 	 
	 	 	 	 	 	 
	By: 	/s/ Thomas Krivas	 	 	 	 
	Name:	Thomas Krivas	 	 	 	 
	Title:	Assistant Secretary	 	 	 	 
	 	 	 	 	 	 
	AB Technologies LLC	 	 	 	 
	 	 	 	 	 	 
	By: 	/s/ Nicholas Khadder	 	 	 	 
	Name:	Nicholas Khadder 	 	 	 	 
	Title:	President	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	AMYRIS Brasil Ltda.	 	 	 	 
	 	 	 	 	 	 
	By: 	 	 	By:	 	 
	Name:	 	 	Name:	 	 
	Title:	 	 	Title:	 	 

 

 

    	 	A-1	 

    CONFIDENTIAL

    

THIS AGREEMENT IS EXECUTED by the authorized representatives of the
Parties as of the date first written above.

 

 

	AMYRIS, Inc.	 	TOTAL ENERGIES NOUVELLES ACTIVITÉS USA 
	 	 	 	 	 	 
	By: 	 	 	By: 	/s/ B Clement	 
	Name:	 	 	Name:	B Clement	 
	Title:	 	 	Title:	President	 

 

 

The following AMYRIS Affiliates existing as of the Effective Date of
this Agreement hereby acknowledge and approve the licenses granted to TOTAL in Section 2.A and Section 7.E.2 of this
Agreement.

 

	AMYRIS Fuels LLC	 
	 	 	 
	By: 	 	 
	Name:	 	 
	Title:	 	 
	 	 	 
	AB Technologies LLC	 
	 	 	 
	By: 	 	 
	Name:	 	 
	Title:	 	 

 

 

    	 	A-2	 

    CONFIDENTIAL

    

THIS AGREEMENT IS EXECUTED by the authorized representatives of the
Parties as of the date first written above.

 

 

	AMYRIS, Inc.	 	TOTAL ENERGIES NOUVELLES ACTIVITÉS USA 
	 	 	 	 	 	 
	By: 	 	 	By: 	 	 
	Name:	 	 	Name:	 	 
	Title:	 	 	Title:	 	 

 

 

The following AMYRIS Affiliates existing as of the Effective Date of
this Agreement hereby acknowledge and approve the licenses granted to TOTAL in Section 2.A and Section 7.E.2 of this
Agreement.

 

	AMYRIS Fuels LLC	 	 	 	 
	 	 	 	 	 	 
	By: 	 	 	 	 	 
	Name:	 	 	 	 	 
	Title:	 	 	 	 	 
	 	 	 	 	 	 
	AB Technologies LLC	 	 	 	 
	 	 	 	 	 	 
	By: 	 	 	 	 	 
	Name:	 	 	 	 	 
	Title:	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	AMYRIS, Inc.	 	 	 	 
	 	 	 	 	 	 
	By: 	/s/ Eduardo Loosli Silverira	 	By: 	/s/ Giani Ming Valent	 
	Name:	Amyris Brasil Ltda	 	Name:	Amyris Brasil Ltda	 
	 	Eduardo Loosli Silverira	 	 	Giani Ming Valent, PMP	 
	Title:	Vice Presidente Amyris Brasil	 	Title:	Diretor de Engenharia	 

 

 

    	 	A-3	 

    CONFIDENTIAL

    

Exhibit A

 

Commercial Technology Transfer Package

 

  

A commercial
technology transfer package should include the following:

 

	1.	Strain information:
	 	a.	Back-ground strain design information such as strain information, genetic background, sequence information, genetic modifications information.  e.g., 
	 	 	I.	Strain ancestor and lineage of the applicable strain including each of the rational or directed strain engineering changes, what type of changes – deletion, insertion, ploidy changes, description of the changes, locus at which the changes were engineered and what were the resulting genii of the modified strain at each step.
	 	 	 	 
	 	b.	Strain storage and propagation 
	 	 	I.	SOP for the overall strain storage including detailed media recipes for preserving strain 
	 	 	II.	SOP for strain revival including steps all the way from seed vial to inoculums tanks for the propagation media for revival of the strain 
	 	 	 	 
	 	c.	Feed-stock information – ingredient information, sourcing, specificities, testing
	 	 	I.	Feed-stock sources and details of handling the feedstock 
	 	 	 	 
	2.	Details of a fermentation run at all scales (including from inoculum to shake-flask to 300L to 1m3, 40 m3 and 200 m3 production reactors):
	 	a.	SOP’s for media, sterilization, fill and draw 
	 	b.	Sampling intervals, sampling protocols
	 	c.	Performance and specific testing at each step, protocols for tests at each stage 
	 	d.	Historical data of runs at  all scales (including 1m3, 40 m3 and 200 m3) to register and monitor variability
	 	  	 	 
	3.	Process design (including Brotas data):
	 	a.	Detailed manufacturing process, process narrative, operating conditions 
	 	b.	PFD’s design basis, heat/material balance, with identified streams
	 	c.	Equipment list and material of construction – vessel specifications, identify an special modifications, performance required, design and fabrication codes, vendor and model numbers
	 	d.	Utility flow and diagrams – all major inputs, outputs, stream compositions, flow rates
	 	e.	Waste-water specification
	 	f.	Routine maintenance, testing, replacements

 

    	 	A-4	 

    CONFIDENTIAL

    

	 	 	 	 
	4.	Process book including process control and details of the operation:
	 	a.	Aseptic design and operation,  sterilization and cleaning (SIP/CIP) procedures and schedules 
	 	b.	batch and fed-batch operational details, 
	 	c.	feeding algorithm details, 
	 	d.	process control and monitoring strategies
	 	e.	historic data of all prior runs with the strains – access to database of prior runs

 

 

And any other information that is necessary
for being able to operate the strain in commercial settings.

 

 

 

 

 

 

 

    	 	A-5	 

    CONFIDENTIAL

    

 

Exhibit B

 

Initial Package

 

 

Current process book for the current strain Amyris
is using for the commercial production of farnesene and the following with respect to the all of the designated Intermediate Strains:

 

	1.	Strain information:
	 	a.	Back-ground strain design information such as strain information, genetic background, sequence information, genetic modifications information.  e.g., 
	 	 	I.	Strain ancestor and lineage of the current strain including each of the rational or directed strain engineering changes, what type of changes – deletion, insertion, ploidy changes, description of the changes, locus at which the changes were engineered and what were the resulting genii of the modified strain at each step.
	 	b.	Strain storage and propagation 
	 	 	 	i.	SOP for the overall strain storage including detailed media recipes for preserving strain 
	 	 	 	ii.	SOP for strain revival including steps all the way from seed vial to inoculums tanks for the propagation media for revival of the strain
	 	c.	Feed-stock information – ingredient information, sourcing, specificities, testing
	 	 	 	 	I.	Feed-stock sources and details of handling the feedstock 
	 	 	 	 	II.	Testing results for content of sugar or other impacting ingredients
	 	 	 	 	III.	Seasonal variation information or data 
	 	 	 	 	IV.	Protocols for any adjustment made to feedstock
	 	 	 	 	 	 
	2.	Current best details of a fermentation run at all scales (including from inoculum to shake-flask to 300L to 1m3, 40 m3 and 200 m3 production reactors - if not at the largest scale then information on best scale at which this strain is current been running):
	 	a.	SOP’s for media, sterilization, fill and draw 
	 	b.	Sampling intervals, sampling protocols
	 	c.	Performance and specific testing at each step, protocols for tests at each stage 
	 	d.	Historical data of runs at all scales (including 1m3, 40 m3 and 200 m3) to register and monitor variability
	3.	Current best process design (including Brotas data):
	 	a.	Detailed manufacturing process, process narrative, operating conditions 
	 	b.	PFD’s design basis, heat/material balance, with identified streams
	 	c.	Equipment list and material of construction – vessel specifications, identify an special modifications, performance required, design and fabrication codes, vendor and model numbers
	 	d.	Utility flow and diagrams – all major inputs, outputs, stream compositions, flow rates
	 	e.	Waste-water specification	 
	 	f.	Routine maintenance, testing, replacements

 

    	 	B-1	 

    CONFIDENTIAL

    

	4.	Current best process book including process control and details of the operation:
	 	a.	Aseptic design and operation, design constraints,  sterilization and cleaning (SIP/CIP) procedures and schedules 
	 	b.	batch and fed-batch operational details, 
	 	c.	feeding algorithm details, 
	 	d.	process control and monitoring strategies
	 	e.	Performance data of recent runs 

 

Any other information that is necessary for being
able to operate the strain in commercial settings.

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	B-2	 

    CONFIDENTIAL

    

Exhibit C

 

List of the Member States of the European Union

 

The following States are members of the European
Union as of the Effective Date:

 

		1.	Austria

		2.	Belgium

		3.	Bulgaria

		4.	Croatia

		5.	Cyprus

		6.	Czech Republic

		7.	Denmark

		8.	Estonia

		9.	Finland

		10.	France

		11.	Germany

		12.	Greece

		13.	Hungary

		14.	Ireland

		15.	Italy

		16.	Latvia

		17.	Lithuania

		18.	Luxembourg

		19.	Malta

		20.	Netherlands

		21.	Poland

		22.	Portugal

		23.	Romania

		24.	Slovakia

		25.	Slovenia

		26.	Spain

		27.	Sweden

		28.	United Kingdom

 

 

 

    	 	C-1	 

    CONFIDENTIAL

    

Exhibit D

 

Known By-Products

 

		1.	Identified as of the Effective Date: The following compositions: (i) dead yeast cells, (ii)
ethanol, (iii) farnesol, (iv) farnesene dimer, (v) triglyceride, (vi) hexahydrofarnesol, (vii) hydrogenated farnesene dimer, or
(viii) combination of items in (i) through (vii) with or without farnesene and/or farnesane.

 

		2.	Identified after the Effective Date:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

D-1Exhibit 10.06

 

 

CONFIDENTIAL

 

	CONFIDENTIAL
TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,
WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

Amendment #1 to IP LICENSE
AGREEMENT

 

THIS AMENDMENT #1 TO THE IP LICENSE AGREEMENT (“First
Amendment”) is made and entered into as of March 21, 2016 (the “First Amendment Effective Date”) by
and between Amyris, Inc., having its principal place of business located at 5885 Hollis St, Suite 100, Emeryville, CA 94608
USA (“Amyris”), and Novvi LLC, a Delaware limited liability corporation, having its place of business
at 5885 Hollis Street, Suite 100, Emeryville, California 94608 (“Novvi LLC”).

 

WHEREAS, Amyris and Novvi LLC entered into that certain
IP License Agreement on March 26, 2013 (the “License Agreement”) whereby Amyris agreed to license, on the terms
and conditions set forth in the License Agreement, certain of its intellectual property rights to Novvi LLC;

 

WHEREAS, such License Agreement was clarified by Novvi LLC, Total
Amyris BioSolutions B.V. (“TAB”), and Amyris in an Amended and Restated Letter Agreement Containing Clarifications
to the IP License Agreement dated November 30, 2013, which stated that certain By-Products would be sold only to Amyris or TAB,
and Novvi LLC would retain the ability to sell other By-Products to third parties;

 

WHEREAS, pursuant to the terms and conditions of this First
Amendment, the Parties desire to amend the License Agreement to clarify that Novvi LLC may offer for sale or sell its By-Products,
including Diesel By-Products, for any use excluding any use in or as (i) diesel fuel in the European Union and (ii) jet fuel worldwide.

 

NOW THEREFORE, in consideration of the promises and the mutual
covenants contained herein, the Parties agree as follows:

 

		1.	The Parties add the following new definition to Article 1 of the License Agreement:

 

““European Union” means those
countries that were members of the European Union as the effective date of Amendment #1 to the IP License Agreement, which countries
are listed on Exhibit A to such amendment.”

 

		2.	Section 2.1(a)(ii) of the License Agreement is revised to provide in its entirety as follows:

 

“(ii) subject to the limitations in Article 4
restricting the sale of By-Products for use in or as (i) diesel fuel in the European Union and (ii) jet fuel worldwide, a non-exclusive,
worldwide, royalty-free, non-sublicensable, and non-assignable license under Amyris Base Technology to offer for sale, sell, and
import any By-Products.”

 

For clarity, other than the specific changes to clause
(ii) set forth above, the remainder of Section 2.1(a) of the License Agreement, including clause (i) and the two paragraphs immediately
following the amended text above, remains as is and is not deleted, modified, or amended hereby.

 

		3.	Article 4 of the License Agreement is hereby amended by deleting such Article in its entirety and
replacing it with the following new Article 4:

 

“ARTICLE 4

 

SALE OF BY-PRODUCTS 

 

4.1      No Sale of By-Products as
Diesel Fuel in the European Union. Novvi LLC agrees that it shall not, at any time, offer for sale or sell any By-Products,
including, but not limited to, any farnesane or diesel-related By-Products (“Diesel By-Products”), for use in
or as diesel fuel in any of the European Union.

 

4.2      No Sale of Jet Fuel By-Products
except to Amyris; Amyris’s Obligation to Purchase.

 

    	 	Page 1 of 4	 

     

    

(a)                
Novvi LLC agrees that it will not offer for sale or sell any Jet Fuel By-Products to any person or entity except to Amyris as set
forth in this Section 4.2, and Amyris agrees that it will purchase all such Jet Fuel By-Products. As used in this Section, “Jet
Fuel By-Product” means a By-Product (i) whose concentration of farnesane, partially hydrogenated farnesene or farnesene,
by volume, is at least [*] or greater; and (ii) that when blended with petroleum-derived jet fuel, meets the ASTM D1655 and D7566
specifications (or successors thereto) for use as a jet fuel.

 

(b)                
The purchase price payable by Amyris to Novvi LLC for each liter of any Jet Fuel By-Product will be equal to the price per liter
that Amyris sells farnesene to Novvi LLC, in case such price is higher than [*] per liter. If the per liter of farnesene price
Amyris charges to Novvi LLC is below [*] per liter, Amyris will purchase such Jet Fuel By-Product at the NYMEX ULSD diesel one-month
forward price.

 

(c)  In connection with the
sale of any By-Products by Novvi LLC to a third party, Novvi LLC shall require any such purchaser to agree in writing that (i)
such By-Products may not be used in or as diesel fuel in the European Union or in or as jet fuels anywhere, and (ii) if any such
By-Products are incorporated into any diesel fuel outside the European Union, that such diesel fuels may not be imported into any
of the European Union.

 

(d)  Other than as set forth
in this Section, Amyris has no obligation or rights to purchase any By-Products from Novvi LLC.

 

4.3No Other Limits on Novvi LLC. Other
than as set forth in this Article 4, Novvi LLC may, pursuant to its license in Section 2.1(a)(ii), freely offer for sale,
sell, and import its By-Products.

 

		4.	Capitalized terms used in this First Amendment shall have the same meaning as defined in the License
Agreement unless otherwise defined herein. Except as specifically provided in this First Amendment, the terms and conditions of
the License Agreement shall remain in full force and effect. Together, the License Agreement and this First Amendment constitute
the entire agreement between the Parties with respect to the subject matter, and supersede any and all prior negotiations, representations,
correspondence, understandings and agreements with respect to the subject matter. To the extent of any conflict between the License
Agreement and this First Amendment, this First Amendment shall supersede and govern. This First Amendment may be executed in counterparts,
which together shall constitute one document and be binding on all of the Parties.

 

 

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY BLANK]

 

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

 

    	 	Page 2 of 4	 

     

    

 

IN WITNESS WHEREOF, and intending to be bound by the provisions
hereof, the Parties have caused this First Amendment to be executed personally or by their duly authorized representatives, to
be effective as of the First Amendment Effective Date.

 

	AMYRIS, INC. 	 	NOVVI LLC	 
	 	 	 	 	 	 
	/s/ Nicholas Khadder	 	/s/ Jeffrey Brown	 
	By:	Nicholas Khadder	 	By:	Jeffrey Brown	 
	Title:	General Counsel	 	Title:	President & CEO	 
	 	 	 	 	 	 
	 	 	 	/s/ John L. Carnahan	 
	 	 	 	By:	John L. Carnahan	 
	 	 	 	Title:	Chief Operating Officer	 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	Page 3 of 4	 

     

    

 

Exhibit A

 

Definition of European Union

 

 

 

		1.	Austria

		2.	Belgium

		3.	Bulgaria

		4.	Croatia

		5.	Cyprus

		6.	Czech Republic

		7.	Denmark

		8.	Estonia

		9.	Finland

		10.	France

		11.	Germany

		12.	Greece

		13.	Hungary

		14.	Ireland

		15.	Italy

		16.	Latvia

		17.	Lithuania

		18.	Luxembourg

		19.	Malta

		20.	Netherlands

		21.	Poland

		22.	Portugal

		23.	Romania

		24.	Slovakia

		25.	Slovenia

		26.	Spain

		27.	Sweden

		28.	United Kingdom

 

 

 

 

 

Page 4 of 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]